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ABSTRACT
The potential treatment approaches for various disorders associated with central nervous system
are invasive and do not allow frequent administration. Brain targeting of drugs by intranasal
route is a safe and noninvasive method of drug delivery which allows frequent administration
and is certainly more patient compliant than the currently followed invasive methods.
In this study, the plausibility of delivering neurotrophins [nerve growth factor (NGF) and
brain derived neurotrophic factor (BDNF)], neurotrophinogenic agents (ex: carnosic acid) and
antibiotics (ex: cefotaxime) to brain via nose-brain pathway using chitosan as barrier modulating
agent was investigated. In vitro permeation studies of fluorescein isothiocyanate dextran
(FD40k) across bovine olfactory mucosa using different viscosity grades chitosan at different
concentrations indicated that medium viscosity grade chitosan (0.25% w/v) enhanced the
permeation of FD40k significantly over other grades and concentration of chitosan. Such similar
results were observed when medium viscosity grade chitosan (0.25% w/v) was used as barrier
modulating agent in studies involving nerve growth factor, brain derived neurotrophic factor,
carnosic acid and cefotaxime.
The potential of intranasal formulations of therapeutic agents containing medium
viscosity grade chitosan (0.25% w/v) was explored by carrying out in vivo studies in male
Sprague-Dawley rats.
The brain bioavailability of group of rats administered intranasally with NGF and BDNF
solution containing chitosan was significantly enhanced by ~14 fold and ~13 fold, respectively,
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compared to group of rats administered with same concentration of NGF and BDNF solution
without chitosan. Pharmacodynamic studies clearly indicated that the immobility time in case of
rats subjected to immobilization stress was significantly decreased upon intranasal administration
of BDNF solution containing chitosan.
In studies involving carnosic acid the neurotrophin levels (NGF and BDNF) were
enhanced significantly upon intranasal administration of carnosic acid with chitosan, which was
~1.5-2 fold more over the parenteral route. When carnosic acid with chitosan formulations were
administered in the form of nanoparticles only once in contrary to that of solution which was
administered daily once for a period of 4 days there was no statistically significant difference in
the NGF and BDNF levels. However, when the formulations were administered in the form of
solution only once, the NGF and BDNF levels even after 4 days were not statistically significant
from the vehicle control group. The results clearly indicated that carnosic acid nanoparticles
could reduce the frequency of administration and also could maintain prolonged therapeutic
levels due to higher retention time at the site of delivery.
The pharmacokinetic studies of cefotaxime indicated that the drug levels attained in the
brain following i.v and intranasal administrations were comparable. However, the drug levels in
the plasma following intranasal administration were almost an order of magnitude less when
compared to that of i.v administration. These results suggested that intranasal administration of
cefotaxime along with chitosan is likely to result in less systemic side effects compared to
parenteral administration.
Nose to brain delivery of therapeutic agents along with chitosan as barrier modulating
agent is a potential approach for treating various disorders associated with central nervous
system.
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CHAPTER-1
I TRODUCTIO

1.1. Anatomy of nose
The human nasal cavity is divided into two cavities by the nasal septum. Each nasal cavity
(surface area ~75 cm2) has three distinct regions, the vestibular, respiratory and olfactory
regions. The vestibular region is located at the opening of the nasal passage and is responsible
for filtering of air borne particles and has no absorption function. The respiratory region covers
most of the dorsal and ventral nasal cavities and is primarily responsible for drug absorption as it
has the highest degree of vascularity. The olfactory region plays an important role in
transportation of drugs to the brain and the cerebrospinal fluid (CSF) and it constitutes ~10 cm2
in surface area. The olfactory region is situated just below the cribriform plate of the ethamoid
bone separating the cranial cavity from the nasal cavity (1, 2).

Figure 1: Schematic illustration of human nose indicating the various cell types in the olfactory
region. [Hilger PA, Fundamentals of Otolaryngology, A Textbook of Ear, #ose and Throat
Diseases. 6th ed. Philadelphia, PA, 184, Copyright Elsevier (WB Saunders Co) (1989)].
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The olfactory epithelium is a modified form of respiratory epithelium consisting of three types of
cells, the olfactory receptor cells, sustentacular cells and basal cells. The olfactory receptor cells
are bipolar neurons and are interspersed among sustentacular cells. A single dendritic process
extends from the cell body to the free apical surface where it terminates as a small knob like
swelling from which extends a dozen of extremely long modified non motile cilia. At the basal
aspect of the neuronal cell body, each receptor gives rise to a single fine non-myelinated axon
and forms large bundles in the lamina propria. The unbranched axons are ensheathed by glial
cells and cross into the cranial cavity through small holes in the cribriform plate of the ethmoid
bone. The bundles of nerve fibers travel along the surface of the olfactory bulb, eventually
synapsing with mitral cell dendrites and other neuronal targets in the glomeruli of the bulb. The
sustentacular cells are elongated columnar cells with many long microvilli extending from their
luminal surface to form an entanglement with the cilia of the receptor cells. These cells provide
mechanical support to the receptor cells. The basal cells are small, conical cells which are able to
differentiate into neuronal receptor cells (1-3).

1.2. Pathways of drug absorption
Intranasally administered drugs reach the brain and/or CSF by different routes as illustrated in
figure 2. A significant amount of drug may be rapidly cleared by the mucociliary mechanism.
Some part of the administered drugs (lipophilic) may directly reach the systemic circulation and
subsequently is eliminated from the blood stream via normal clearance mechanism. The drugs
can reach the brain from the blood by crossing the blood brain barrier but can also be eliminated
from the CSF into the blood (1, 4-6).
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Figure 2: Schematic overview of possible in vivo fate of drugs following intranasal administration.
The drug can also be absorbed from the nasal cavity via the olfactory pathway into the CSF and
possibly further into the brain parenchyma by navigating along one or more of the following
pathways (Figure 3).
a). Paracellular pathway: The transport of drugs by this route is slow and passive. The drugs
pass through the tight junctions and the open clefts of the epithelial cells present in the nasal
mucosa. Low molecular weight and/or hydrophilic drugs are usually transported by this route.
b). Transcellular pathway: The drugs are transported across the nasal epithelium by either
passive diffusion or receptor mediated endocytosis or fluid phase endocytosis. Usually, lipophilic
or large molecular weight compounds are transported by this route.
c). euronal transport: This kind of transport takes place via intercellular axonal transport.
The olfactory neuron cells facilitate the drug transport principally to the olfactory bulb.
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Figure 3: The different pathways of drug absorption from the nasal cavity via olfactory
pathway into brain parenchyma and/or CSF.

1.3. Barriers for drug delivery
From the results of various studies conducted in animal models it has been reported that the
direct uptake of drugs into CSF and/or brain upon intranasal administration is affected by
physico-chemical factors (chemical form, molecular weight, particle size etc.), formulation
factors (pH, drug concentration, gel forming carriers, preservatives, dose volume etc.) and
physiological factors (effect of disposition, mucociliary clearance, enzymatic degradation,
pathological condition etc) (4, 7). Some of the critical factors which limit the brain uptake of
intranasally administered drugs are discussed below.
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a). Low permeability across the olfactory mucosa for polar drugs and macromolecules
The poor bioavailability of polar drugs (~10%) and peptides (< 1%) across nasal mucosa is
attributed to the low membrane permeability (5). Tight junctions, although considered as
dynamic structures which can open and close to a certain degree, the transport of large molecules
is limited across them (8, 9). Hence the bioavailability is poor as the large molecules are
transported across the nasal mucosa by endocytosis. Trans-nasal absorption is greatly improved
by co-administration of absorption enhancing agents. These include cationic compounds
(chitosan and its derivatives, poly-L-arginine, poly-L-lysine), bile salts and bile salts derivatives
(sodium deoxycholate, sodium glycocholate, sodium taurodihydrofusidate), fatty acids and fatty
acid derivatives (linoleic acid), phospholipids (lysophosphatidylcholine) and surfactants (sodium
laurylsulfate). These enhancers act by either altering the permeability of the epithelial cell layer
or act on tight junctions or work as enzymatic degradation inhibitors. In animal studies it has
been reported that there is a direct correlation between the absorption enhancing effect of
surfactants/ bile salts and the damage caused to the nasal mucosa. In contrary, it has been
demonstrated that the cationic compounds such as chitosan causes minimal or no damage to the
nasal mucosa (10).

b). Mucociliary clearance
This is another important factor, which affects the bioavailability of intranasally administered
drugs due to the rapid clearance of the formulation from the nasal cavity. As a result of
mucociliary clearance the contact or retention time of the drug at the absorption site is limited. It
has been reported that for formulations (liquid/powder) which are not bioadhesive the half life
for clearance is of the order of 15-30 minutes in the nasal cavity thereby resulting in incomplete
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drug absorption (7, 11). The only approach to overcome the rapid mucociliary clearance is by
use of bioadhesive excipients in the formulations or by administering the formulation in the less
ciliated part of the nasal cavity thus leading to improved absorption. Vyas et al., observed a
higher transport of drug to rat brain upon intranasal administration of mucoadhesive microemulsions of sumatriptan compared to non-mucoadhesive micro-emulsions (12). Kumar et al.,
also demonstrated that bioadhesive nano-emulsions of risperidone could be rapidly and
efficiently transported to the rat brain upon intranasal administration (13).

c). Enzymatic degradation
The poor bioavailability of intranasally administered peptides and proteins is attributed to the
enzymatic degradation of the molecule in the lumen of the nasal cavity or during passage
through the epithelial barrier (14). These regions of the nasal cavity contain exopeptidases such
as mono and diamino peptidases that can cleave peptides at their N and C terminals and
endopeptidases such as serine and cysteine which can attack internal peptide bonds (15). In
addition, the proteolytic enzymes and other mucosa secretases in the mucosal secretions can
form the enzyme barrier in the nasal cavity which produces a pseudo first pass effect thereby
decreasing the delivery amounts and therapeutic effects of peptides and proteins. In the human
nasal cavity the enzyme isoforms of cytochrome P450 such as CYP1A, CYP2A and CYP2E are
found in addition to carboxylesterases, S-transferases, glutathione etc (4). This enzymatic
degradation of peptides and proteins can be overcome by using enzyme inhibitors/ by saturation
of enzymes. Graff et al., demonstrated that co-administration of verapamil and enzyme
(CYP3A4 and P-gp) substrate resulted in the complete elimination of P-gp mediated transport of
verapamil and significantly enhanced its brain uptake (16).
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1.4. Approaches to enhance nose to brain drug delivery
In addition to the steps taken to overcome the barriers/limitations (low membrane permeability,
mucociliary clearance and enzymatic degradation) upon intranasal delivery, other approaches
which are being investigated to augment the nose to brain delivery are discussed as follows.

a). Prodrug approach
The critical physicochemical factors which influence the direct drug uptake from nose to brain
and/or CSF are molecular weight and lipophilicity. Prodrugs are synthesized with an aim to
modify the structure of the parent drug with favorable physicochemical and biological properties
for absorption (7, 17). Kao et al., reported that intranasal administration of several alkyl ester
water soluble prodrugs of L-dopa to rats resulted in significantly higher levels of L-dopa than
that of the parent drug in the CSF, which was also significantly higher than that of equivalent i.v
dose (18). Enhancement of nose to brain drug delivery by this approach is an effective method.
However, such modification may alter the biological activity of the drugs, for example, synthesis
of protein prodrugs may result from serious disruption of their spatial structures thus
significantly reducing their activity (7).

b). Modification of formulations
The type of formulation also plays an important role on brain uptake of intranasally administered
drugs as they determine the residence time and local drug concentration in the olfactory mucosa
(7). Dalpiaz et al., demonstrated that microparticles of N-cyclopentyladenosine (CPA)
significantly increased the drug delivery to CSF via intranasal administration in rats, while free
CPA was not able to reach the CSF from nasal cavity or by i.v infusion (19). Kumar et al., also
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demonstrated that nano-emuslions of risperidone could be efficiently transported to brain upon
intranasal administration to rats (13).

c). Agglutinant-mediated transport
The saccharide groups, N-acetlyglucosamine and L-fucose which are significantly more
expressed than other saccharide groups present on the nasal mucosa specifically bind to wheat
germ agglutinin (WGA) and ulex europaeus agglutinin (UEA I), respectively, convey signals to
the cells, induce endocytosis and then transit to brain (20). Gao et al., reported that after
intranasal administration of vasoactive intestinal peptide (VIP)-loaded WGA nanoparticles
(lectin-bearing PEG-polylactic acid) in rats, the active VIP amounts were ~6 times higher in
cerebrum than that following an intranasal VIP solution (21-23).

d). Brain homing peptide-mediated
The brain homing peptides are identified by recovering the phage libraries from the brain upon
intranasal administration. The recovered phage libraries are then amplified repeatedly in vitro
and redelivered intranasally to obtain sufficiently enriched peptides to target brain parenchyma
or CSF (7). Then the valid homing motifs are identified and may be grafted to surface molecules
of drugs or preparations like liposomes with specific targeting properties (24). Janda reported
that the cocaine addiction in animal models was effectively treated by delivering the therapeutic
protein agent directly into the central nervous system (CNS) from the nasal cavity by phagebased approach (25).
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1.5. In vitro and In vivo models
The most commonly used in vitro models for routinely carried out transport studies of drugs
across nasal mucosa are excised mucosal tissue or cell culture monolayers (26, 27). From various
nasal mucosal studies it has been reported that fully organized mucosal tissue is mechanistically
more relevant to human nasal mucosa than cell lines. Bovine olfactory mucosa was reported to
be a good in vitro model for human olfactory mucosa with respect to drug transport and
metabolic pathways in nasal mucosa (27).
The transport of various drugs from nasal cavity to brain and/or CSF has been studied in
rats, mice, rabbits and monkeys, however, most of the studies have been performed in rats (1).

a). Transport of low molecular weight drugs in animal models
Many low molecular weight drugs have been shown to be transported directly to the brain and/or
CSF from the nasal cavity (1, 27). Chow et al, studies the brain uptake of cocaine after intranasal
and i.v administration in rats and reported that there was similar distribution of cocaine in the
various regions of the brain. However, the cocaine content in samples collected within 60
minutes after intranasal administration showed highest concentration in the olfactory bulb than
the remaining parts of the brain. From the results of these studies it was concluded that the rapid
effect of cocaine on the CNS was due the presence of direct pathway from the nasal cavity to the
brain (28). Sakane et al., reported that upon intranasal administration of cephalexin in rats, the
levels in the CSF were ~100 fold higher than when administered by i.v/intraduodenal routes (29).
Anand Kumar et al., and David et al., reported that the amount of labeled drugs (oestradiol and
progesterone) that reached the CSF was higher upon intranasal administration in rhesus monkey
compared to i.v administration (1, 30).
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b). Transport of large molecular weight drugs in animal models
A number of protein and peptide drugs have been successfully delivered to the brain and/or CNS
by intranasal route in variety of species (1). Vajdy et al., reported that the plasma DNA reached
the brain within 15 minutes following intranasal administration (31). Liu et al., has investigated
the nose to brain delivery of insulin like growth factor-I (IGF-I) and reported that intranasal
delivery of IGF-I protects against focal cerebral ischemic damage (32). It has been reported that
macromolecules such as interferon-β-1b (MW ~18.5 kDa) and vasoactive intestinal peptide (MW
~3.3 kDa) rapidly achieved peak brain levels upon intranasal administration compared to that
administered by i.v route (33). Alcala-Barraza et al., demonstrated that intranasal delivery of
[125I]–radiolabeled neurotrophic factors, brain derived neurotrophic factor (BDNF), ciliary
neurotrophic factor (CNTF), neurotrophin-4 (NT-4) and erythropoietin resulted in substantial
concentrations within 25 minutes in brain parenchyma (34).
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CHAPTER-2
CHITOSA

Chitosan is a polycationic linear polysaccharide chemically derived by deacetylation of chitin
(1:4- linked 2-acetamide-2-deoxy-β-D-glucopyranose), a naturally occurring polymer present in
shells of crustaceans such as crabs, lobsters, prawns and shrimp (35). Chitosan is available in
different molecular masses (low < 50 kDa, medium 50-150 kDa, high > 150 kDa), degrees of
deacetylation (40 - 98%) and viscosities. It is insoluble at neutral and alkaline pH conditions,
whereas at acidic pH conditions the amino groups are protonated (pKa 6.3) thereby improving the
solubility. This polymer has wide application in biomedical and pharmaceutical fields due to its
biocompatible, biodegradable and non-toxic nature (35-37). Among many polymers, chitosan
has been found to be substantially safe on nasal epithelium (36).
The permeation enhancement property of chitosan when applied to nasal mucosal surface
is attributed to its ability to translocate the proteins zonula occludens-1 (ZO-1) and occludin from
plasma membrane to cytoplasm and promoting the partial alteration of cytoskeleton thus opening
tight junction complexes (38). Chitosan may assist paracellular transport of drugs by transiently
opening the tight junctions existing between the epithelial cells and suppressing the efflux
transporters as has been shown in Caco-2 cell culture studies and in animal models (39, 40).
Schipper et al., studied the influence of molecular weight and degree and acetylation on drug
transport across human intestinal epithelial (Caco-2) cells and reported that increased molecular
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mass and deacetylation degree, improves the chitosan ability to open tight junctions (39).
Dodane et al., investigated the effect of chitosan solutions (degree of deacetylation 80%, pH 66.5) on the structure and function of Caco-2 cell monolayers using microscopy techniques
(confocal and transmission electron microscopy) and reported that chitosan had a transient effect
on the tight junctions permeability and the cells viability was not affected (38). In addition to
chitosan, its thiolated and quaternized derivatives have been reported to enhance the permeability
of the nasal mucosa. Krauland et al., demonstrated that intranasal delivery of insulin thiolated
chitosan to male Wistar rats resulted in significantly higher bioavailability (41). Hamman et al.,
studied the effect of degree of quaternisation of N-trimethyl chitosan chloride (TMC) on
absorption enhancement of [14C]-mannitol, in vivo in rats and reported that all TMC polymers
with different degrees of quaternisation (12-59%) increased the nasal absorption of [14C]mannitol significantly (42). Some reports exist on the ability of chitosan and its derivatives to
improve the bioavailability of macromolecules across the nasal epithelium (10, 43).
Chitosan is bioadhesive at physiological pH due to the ionic interactions between the
positively charged amino groups in chitosan and the negatively charged sialic acid residues in
mucus (39). There is also evidence that chitosan may improve the bioavailability of
macromolecules in the brain when injected i.v or parenterally. For instance, chitosan based
microemulsion significantly increased the brain uptake of i.v injected nobiletin in mice (44).
When doxorubicin loaded chitosan-poly acrylic acid hollow nanospheres are administered
parenterally to different organs of mice, a significant amount of drug reached the brain. Confocal
laser scanning microscopy confirmed that the hollow chitosan-poly acrylic acid nanospheres are
potential carriers for drugs (45). Extensive toxicological and tolerance studies in animal models
and humans have shown chitosan to be non-toxic and non-irritant to the nasal mucosa (46).
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CHAPTER-3
EUROTROPHI S

3.1. Importance of neurotrophins
Neurotrophins comprise a large group of proteins which are synthesized as precursors of
approximately 270 amino acids (30-35 kDa) (47-49). The physiological actions of neurotrophins
(NTs) have been attributed to mature proteins which function as soluble, non-covalently linked
homodimers. NTs are uniquely potent molecules which bind to specific receptors and elicit
biological responses in the nanomolar to femtomolar range (49). The neurotrophin receptors
consist of single low-affinity receptor (p75NTR), a member of tumor necrosis receptor family and
a high-affinity tropomyosin related kinase (trk) receptor which is made up of three distinct
members of trk family (50). Most of these proteins act via retrograde signaling from target
neurons and some NTs function partially, or exclusively as anterograde molecular signals. They
promote the neuronal survival, stimulate axonal growth and influence axonal findings to
establish synaptic contacts during development. In addition neurotrophins also represent a
potential means of modifying astrocytic activation, neuronal dysfunction and inflammatory
reactions under pathological conditions (47, 49, 51). Hence, many of the neurotrophins are used
as therapeutic agents for treating various nervous system disorders and injury states, including
Alzheimer’s, Parkinson’s, multiple sclerosis, motor neuron diseases, stroke and traumatic
brain/spinal cord conditions (51). The mammalian neurotrophin family contains six members,
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nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3),
neurotrophin-4/5 (NT-4/5), neurotrophin-6 (NT-6) and neurotrophin-7 (NT-7) (49).

3.2. Disorders associated with neurotrophin depletion
It has been reported that neurodegenerative disorders such as Alzheimer's, Parkinson's, motor
neuron diseases and stroke are caused due to depletion of endogenous levels of NTs during the
neurodegenerative disorders (47). Alzheimer's disease (AD) is the most common form of
dementia in elderly patients, characterized by memory loss and confusion. During this disease
state there is substantial decline in the cholinergic function in the cortex and hippocampus region
of the brain (52, 53). It has been reported that the degeneration of these cholinergic functions in
AD patients are caused by reduced neurotrophic support that is lack of production of
NGF/BDNF in the cerebral cortex and hippocampus region (51). Parkinson’s disease is
degenerative disorder of the CNS which results in rigidity and tremors of the limbs, postural
instability and bradykinesia of the limbs and body. The symptoms are the result of loss of
pigmented cells in the substantia nigra and due to the reduction of the neurotransmitter dopamine
in the striatum. Peripheral neuropathy includes a range of neurological disorders resulting from
damage to the peripheral nerves. Amyotrophic lateral sclerosis is the most common form of adult
motor neuron disease. In this disease state the motor neurons in the spinal cord, brain stem and
motor cortex progressively die (47-49).

3.3. Current treatment approaches
Currently practiced invasive methods for treating neurodegenerative disorders include
intraparenchymal or intracerebroventricular or intrathecal routes of administration of NTs (49).
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For delivery of NTs locally over short distances in the CNS tissues intraparenchymal route is
preferred. Intraparenchymal route is also ideal for administration of polymer encapsulated
neurotrophin implants or genetically engineered cells for the continuous supply of NTs (54). In
order to deliver NTs to wide areas of the CNS, intracerebroventricular route is preferred as it
results in distribution of NTs within the ventricular and extraventricular CSF (55). Intrathecal
administration of NTs may result in high local concentrations in the subarachnoid spaces of CSF
at the lumbar or cisternal spinal cord levels. This route is not commonly preferred for treating
CNS diseases as the therapeutic levels are rarely attained in contrast to spinal cord diseases (56,
57). The demerits of these routes for administration of NTs are they are invasive, may cause
infection and result in damage of tissue during cannula insertion (49).
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CHAPTER-4
OBJECTIVES

The treatment of neurodegenerative disorders with NTs has been a challenging task as most of
them are not successful in clinical trials due to the poor efficiency of current drug delivery
methods (58). It has been reported that upon intraventricular or intrathecal infusion of NTs there
was distribution of the neurotrophins throughout the subarachnoid space of the brain and spinal
cord, inducing migration of Schwann cells into the CNS, stimulating nociceptive axons, eliciting
sympathetic axon sprouting around the cerebral vasculature thereby causing weight loss (49).
Thus, clinical testing of NTs requires a delivery method that is non-invasive, patient compliant
and effective in delivering therapeutic amounts of NTs to the brain for the treatment of
neurodegenerative disorders.
Intranasal administration is a potential route for drug delivery to the brain that bypasses
the blood–brain barrier (BBB). This route of administration is relatively more patient compliant
than injections and also allows more frequent administration due to its noninvasiveness.
The objective of our study was to investigate the potential of chitosan in enhancing the
transport of neurotrophins (NGF and BDNF) and neurotrophinogenic agents (ex: carnosic acid)
via nose to brain pathway thereby enhancing the brain uptake. The other objective was to study
the pharmacokinetics of these drugs in the perineural fluid employing brain microdialysis
technique following intranasal administration.
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CHAPTER-5
ERVE GROWTH FACTOR

Nerve growth factor (NGF) a member of neurotrophin family synthesized primarily in the
hippocampus and neocortex of the brain plays a significant role in promoting growth,
differentiation and function of both peripheral ganglion cells and central cholinergic neurons of
the basal forebrain (59-61). NGF was the first neurotrophins family member and the first nervous
system growth factor to be identified. NGF was originally isolated from mouse sarcoma based on
its ability to promote the hypertrophy and fiber outgrowth from sensory neurons. NGF is a
hydrophilic, dimeric protein of ~30 kDa and is not bioavailable to the brain on systemic
administration due to the brain barriers (61). Prior studies on nose to brain delivery of NGF have
used the total amount of NGF in the brain tissue homogenate as a measure of successful delivery
(59, 62). However, the NGF concentration in brain interstitium (perineural fluid that bathes the
neuronal cell surfaces) as opposed to total concentration in the brain tissue is more relevant in
predicting the therapeutic effectiveness, adverse effects, and toxicity of neurotrophins. Therefore,
the time course of concentration of the NGF in the brain interstitial fluid following intranasal
delivery of NGF was investigated using microdialysis sampling technique.
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5.1. Materials and Methods
5.1.1. Chemicals
Krebs-Ringer bicarbonate (KRB) buffer (premixed powder), crystal violet, gelatin (300 bloom),
fluorescein isothiocyanate dextran of molecular weight 40 kDa (FD40K), chitosan of different
grades, low viscosity (20-200 cP), medium viscosity (200-800 cP) and high viscosity (800-2000
cP) with varying percentage of deacetylation content were procured from Sigma chemicals
(St.Louis, MO). NGF, 2.5 S, murine and NGF Emax ImmunoAssay system were purchased from
Promega Corporation, Madison, WI.

5.1.2. Olfactory mucosa
The bovine olfactory mucosa was purchased from Pel-Freez Biologicals, Arkansas. Bovine
olfactory mucosa is a good model for human olfactory mucosa with respect to drug transport and
metabolic pathways in nasal mucosa (27). The tissue was excised freshly and supplied frozen.
The tissue was used within 24 h of excision. The tissue was thawed for 30 minutes before
mounting on the diffusion cell.

5.1.3. In vitro experimental set up
A vertical Franz diffusion cell (Logan instruments, Somerset, NJ) was used for permeation
experiments across the bovine olfactory mucosa. The temperature of the chamber was regulated
at 37 ± 10C by water circulation. Bovine olfactory mucosa was sandwiched between two
compartments of the diffusion apparatus, one serving as the donor and other as the receiver
compartment. The olfactory mucosa side was in contact with the upper donor compartment and
the ventral side with the receiver compartment. The active diffusion area was 0.64 cm2.
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Silver/Silver chloride (Ag/AgCl) electrode wires of 0.5 mm in diameter (obtained from Alfa
Aesar, Ward Hill, MA) made in the form of circular ring were placed 2 mm away from the
olfactory mucosa in both donor and the receiver compartments. The donor and the receiver
compartments were filled with 100 µL and 5 mL KRB buffer, respectively for electrical
resistance measurements. The AC electrical resistance of the mucosa was measured by placing a
load resistor RL (100 kΩ) in series with the mucosa. Voltage drop across the whole circuit (VO)
and across the mucosa (VE) was measured using an electrical set up consisting of a wave form
generator and multimeter (Agilent Technologies, Santa Clara, CA). For measuring the resistance,
a small voltage of 100 mV was applied at 10 Hz and the olfactory mucosa resistance in kΩcm2
was approximated from the following formula.

RE =

VERL
VO −VE

Where, RE is the olfactory mucosa resistance and RL is the load resistor in kΩ.

5.1.4. Preparation of chitosan and FD40K/ GF solution
Different grades of chitosan solutions were prepared by dissolving required quantity of chitosan
in a fraction of 1% glacial acetic acid solution prepared in KRB buffer (pH 5.5). The second
fraction of the KRB buffer was used to dissolve the FD40K/ NGF. The FD40K/ NGF and
chitosan solutions were mixed by vortexing. The solutions prepared without incorporation of
chitosan served as control.
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5.1.5. In vitro permeation studies
In order to investigate the effect of different viscosity grades chitosan (low viscosity, medium
viscosity and high viscosity) on the permeation of FD40K, the donor solution was replaced after
equilibration for 30 minutes with a solution of 500 µL of FD40K (1mg/mL) with different
concentrations of chitosan (0.1% or 0.25% or 0.5% w/v). The receiver compartment was filled
with 5 mL KRB buffer. Samples were collected at the end of 2 h from the receiver compartment
and the amount of FD40K permeated across bovine olfactory mucosa was determined by
measuring the fluorescence emission intensity at 520 nm by excitation at 494 nm using Perkin
Elmer fluorimeter. In control set of experiments chitosan was not incorporated in the donor
solution.
In another set of studies the donor compartment was filled with 100 µL of NGF solution
(100 µg/mL prepared in KRB) with medium viscosity grade chitosan of different concentrations
(0.1% or 0.25% or 0.5% w/v) and the receiver compartment with 5 mL KRB buffer. Control set
of experiments were run without incorporation of chitosan in the donor solution. The amount of
NGF permeated across the bovine olfactory mucosa was determined by assaying the samples
collected from the receiver compartment at the end of 2 h by Enzyme-linked immunosorbent
assay (ELISA) using “NGF Emax ImmunoAssay system” (see section 5.1.8).

5.1.6. Calibration of microdialysis probe
The calibration of microdialysis probes (CMA 12, membrane length - 4 mm, diameter 0.5 mm,
stainless steel shaft diameter 0.64 mm, shaft length 14 mm and MWCO 100 kDa) was carried out
by successively immersing the probes in dialysis media containing 50, 75 and 100 µg/mL of
NGF and continuously perfusing with KRB buffer at a flow rate of 2.0 µL/min using a syringe
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pump controller (BASi, West Lafayette, IN). Probes were equilibrated for a period of 30 minutes
and then the samples were collected at regular intervals of 1h for a period of 6 h. The percentage
recovery was calculated as the ratio of dialysate concentration to its concentration in the dialysis
medium surrounding the probe.

5.1.7. In vivo brain microdialysis
In vivo experiments were carried out in male, Sprague dawley rats (250–300 g, Harlan Company,
Indianapolis, IN, U.S.A.) under ketamine (80 mg/kg) and xylazine (10 mg/kg) anesthesia (i.p
injection). The experimental procedures were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Mississippi (Protocol # 07–025). The rats were divided
into 3 groups (n=3 for each).
Intranasal vehicle control group (0.25% w/v chitosan in KRB buffer); Intranasal NGF
group (NGF solution prepared in KRB buffer); Intranasal NGF + Chitosan group (NGF solution
prepared in 0.25% w/v chitosan in KRB buffer).
The procedure followed for carrying out microdialysis is briefly discussed as follows:
Step 1) All the instruments used were clean and sterilized.
Step 2) The rats were anesthetized and the head was shaved.
Step 3) The animals were laid on their back and the formulations were administered intranasally
using a using a microsyringe connected with a soft polymer capillary directly into the posterior
segment of the nose.
Step 4) After 30 minutes, the animals were placed on the stereotaxic frame (Harvard instruments, Holliston, MA) by putting the ear bars into the ear canals such that the animal is locked
correctly. This was confirmed as there was no lateral movement of the head.
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Step 5) The front teeth of the rat was put over the incisor bar and was slided away from the
animal as far as possible to lock the head. The nose clamp was then tightened.
Step 6) The shaved part of head was cleaned with iodine and incision was made with a scalpel.
Using retractors the skull was exposed and to minimize blood from the wound area, epinephrine
(100µg/mL) was used.
Step 7) The skull was scraped to remove the adhering tissue so that bregma (reference point for
stereotaxic surgery of the brain) is easily distinguishable.
Step 8) The probe holder was adjusted such that its tip exactly points the bregma. The values of
the three coordinates (dorso-ventral, medio-lateral and anterio-posterior) were recorded by
reading the vernier scale.
Step 9) The appropriate coordinates for drilling a hole in the hippocampus region of the rat brain
were calculated.
Step 10) Using a dentist’s drill a hole was made carefully in the hippocampus region such that
the drill goes only through the skull without damaging the blood vessels.
Step 11) After the hole is drilled, using a small needle the dura mater (the outermost layer of the
meninges surrounding the brain) was punctured.
Step 12) Microdialysis probe was fixed on to the probe holder and slowly inserted into the hole
drilled in the hippocampus region (anterior-posterior = 5.6 mm, medio-lateral = 5 mm, dorsoventral = 7 mm, from bregma).
Step 13) Using a microinjection pump, the microdialysis probes were equilibrated by perfusing
KRB buffer at a rate of 2 µL/min for a period of one hour.
Step 14) The animals were given maintenance doses of anesthesia (ketamine 40 mg/kg +
xylazine 10 mg/kg) intravenously as needed.
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Step 15) The microdialysis fractions were collected at hourly intervals for 6 h following
intranasal administration and the dialysate was assayed by ELISA (see section 5.1.8).

Figure 4: Pictorial representation of the stereotaxic frame used for carrying out microdialysis
in rats.
The change in the concentration of NGF over time was used to calculate the pharmacokinetic
parameters using a noncompartmental pharmacokinetic model. The area under the curve was
calculated by trapezoidal rule. The maximum concentration (Cmax) was directly read from the
plot.

5.1.8. Assay of GF
The NGF in the receiver compartments from in vitro experiments and the microdialysates from
in vivo studies were assayed by ELISA using “NGF Emax ImmunoAssay system”. ELISA is
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capable of discriminating the intact peptide from its metabolites and reflects only the actual
content of NGF, unlike in the case of radiolabeled substrates where the label could be associated
either with intact neurotrophins or its metabolite such that measuring the total label content does
not reflect the actual concentration of neurotrophins (60, 63).
Elisa procedure:
Step 1) The required number of wells were coated with 100 µL of carbonate coating buffer
(0.025 M sodium bicarbonate and 0.025 M sodium carbonate, pH 9.7) containing anti-NGF pAb.
The wells are covered and incubated overnight at 40C so that the antibody adheres to the plastic
through charge interactions.
Step 2) The wells were washed once with wash buffer (20 mM Tris-HCl, 150 mM sodium
chloride, 0.05% (v/v) tween 20) and 200 µL of Block & Sample buffer 1X was added and
incubated for 1h at room temperature so as to bind the non specific binding sites.
Step 3) The wells were washed once with wash buffer and NGF standard (100 µL) were added
to each well of the first column by performing serial dilutions. Samples to be analyzed were
added to the wells starting from the second column. The wells were incubated with shaking for 6
h at room temperature.
Step 4) After 6 h the wells were washed 5 times using the wash buffer and 100 µL of Block &
Sample buffer 1X containing Anti-NGF mAb was added and incubated overnight without
shaking at 40C.
Step 5) The wells were washed 5 times using the wash buffer and 100 µL of Block & Sample
buffer 1X containing Anti-rat IgG, horseradish peroxidase (HRP) conjugate was added and
incubated for 2.5 h at room temperature.
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Step 6) The wells were washed 5 times using the wash buffer and 100 µL of TMB (3, 3’, 5,5”tetramethylbenzidine) solution was added to each well and incubated with shaking for 10
minutes at room temperature. The addition of TMB resulted in production of blue color due to
the reaction between TMB substrate and HRP conjugate.
Step 7) After 10 minutes the reaction was stopped by adding 100 µL of 1 N HCl and the samples
were analyzed using a plate reader at 450 nm.
The amount of NGF in the samples is proportional to the color generated in the
oxidation-reduction reaction. The sensitivity of the NGF assay was about 7.8 pg/mL.

5.1.9. Microscopic studies
The probe implantation site was examined by microscopic examination of coronal brain sections.
The rats were euthanized via carbon dioxide inhalation. Brains were placed in formalin for 5
days and then embedded in 8% w/w gelatin. The gel block was hardened and cryoprotected in
20% w/w sucrose formalin for 2 days before sectioning at 50 µm on a Leica 1800 cryostat.
Sections were mounted, stained with cresyl violet, and cover slipped with dibutyl phthalate
xylene (DPX).

5.1.10. Statistical analysis
Statistical analysis was carried out using Graph Pad Prism 5 software. The unpaired t-test was
selected as the test of significance and p value less than 0.05 was considered as level of
significance.
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5.2. Results and Discussion
5.2.1. Screening of different grades of chitosan for potential enhancer
Chitosan has been shown to render the olfactory mucosa more permeable to macromolecules.
The mechanism was speculated to be due to opening of tight junctions in the mucosa which
opens up convective transport channels across the barrier (3, 64, 65).
Invariably, all the chitosan grades (low viscosity, medium viscosity and high viscosity) at
three different concentrations (0.1% or 0.25% or 0.5% w/v) used in this study were able to
enhance the permeation of FD40K across the olfactory mucosa at the end of 2 h (Figure 5).
However, the extent of enhancement differed between different grades and concentrations. In
general the enhancement factor decreased at 0.5% w/v chitosan concentration in all the cases
which is likely due to increased viscosity of the donor solution.

Figure 5: Effect of different grades of chitosan [low viscosity (LCH), medium viscosity (MCH)
and high viscosity (HCH)] at different concentration on in vitro permeation of FD40K across
bovine olfactory mucosa. The data points provided are an average of six trails with SEM as
error bars.
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The medium viscosity grade chitosan was more efficient compared to other two grades of
chitosan as a permeation enhancer. The medium viscosity grade chitosan enhanced the
permeation of FD40K by ~7 fold, ~11 fold and ~11 fold at 0.1%, 0.25% and 0.5% w/v
concentration respectively, over control (0.06 ± 0.52 µg/cm2). Therefore, this grade of chitosan
was used to investigate the effect on permeation of NGF in in vitro studies.

5.2.2. In vitro permeation studies
Medium viscosity grade chitosan enhanced the NGF permeation across the bovine olfactory
mucosa by ~8 fold, ~45 fold and ~37 fold at 0.1%, 0.25% and 0.5% w/v concentration
respectively, over control (0.10 ± 0.02 ng/cm2) (Figure 6).

Figure 6: Effect of medium viscosity grade chitosan (MCH) at different concentrations on in
vitro permeation of #GF across bovine olfactory mucosa. The data points provided are an
average of six trails with SEM as error bars.
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However, there was no statistically significant (p > 0.05) difference in the permeation of NGF
when 0.25% and 0.5% w/v chitosan was used. Therefore, 0.25% w/v chitosan was used for all
our future studies.
In order to determine the effect of chitosan on permeability status of the olfactory
mucosa, the electrical resistance was monitored before and after incorporation of chitosan.
Trans-olfactory epithelial electrical resistance has been reported to reflect the permeability status
of the epithelial membranes (66). Therefore, the electrical resistance was measured in the current
studies and the membranes with resistance > 2 kΩ cm2 only were used or the in vitro permeation
studies. In presence of the chitosan the trans-olfactory epithelial electrical resistance dropped
significantly (p = 0.003) by ~34.50 ± 4.06% after 30 minutes indicating the ability of the
chitosan to permeabilize the olfactory mucosa. Electrical resistance is considered to be a rather
qualitative parameter and did not show any quantitative dependence on the concentration of the
enhancer. The most intriguing observation of the study was the recovery of trans-olfactory
epithelial electrical resistance following replacement of chitosan with the KBR buffer in the
donor compartment after the permeation studies. The electrical resistance of the membrane was
found to recover almost completely within 1-2 h (Figure 7).
This suggests that chitosan acts as an enhancer by a mechanism which permeabilizes the
membrane reversibly and not by mechanical disruption of the membrane. Similar observations
found with chitosan in other biological membranes have been attributed to the opening and
closing of tight junctions during permeabilization and recovery phases respectively (38, 67).
Based on these observations, it can be speculated that chitosan could be acting as a drug
permeation enhancer across the olfactory mucosa by opening the tight junctions.
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Figure 7: Relative electrically resistivity of the bovine olfactory mucosa during permeation
studies. After 6 h of permeation study, the #GF solution in the donor compartment was
replaced with KRB buffer and the electrical resistivity was monitored (recovery phase). The
data points provided are an average of six trials and error bars represent the standard error of
mean (SEM).
5.2.3. In vivo brain microdialysis
The drug level in the extracellular fluid is known to determine the drug activity and toxicity in
any tissue. Microdialysis is a technique which is most commonly used to investigate the release
of neurotransmitters in the brain (68-72). The technique is capable of sampling the drug from the
perineural fluid of the brain. Therefore, microdialysis was carried out to investigate the time
course of free NGF in the perineural fluid. Moreover, CNS disorders such as Alzheimer’s and
Parkinson’s are caused by degeneration of neurons specifically in the hippocampus region. The
nose to brain pathway for drugs is well established and has been reported to deliver the NGF
directly to the hippocampus region of the brain where most of the NGF receptors are situated
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(62). Therefore, in the present study, the nose to brain delivery of NGF was investigated by
carrying out brain microdialysis in the hippocampal region.

Figure 8: A representative photomicrograph showing insertion of microdialysis probe into
hippocampus region of rat brain during brain microdialysis (a) and the probe implantation site
which included the rat hippocampal region (b).

The recovery of the microdialysis probe was 4.2 ± 0.3%. The basal value of unbound NGF in
rats was 163.31 ± 3.36 pg/mL. The basal NGF levels observed in our studies are lower than that
reported in prior studies. Hoener et al., determined the endogenous level of NGF in rat
hippocampus as 738 pg/mL (73). The same was reported to be 1336 pg/mL by Fawcett et al (74).
This could be due to the fact that the previous reports on nose to brain delivery of NGF were
based on the measurements of NGF in whole tissue homogenates (62, 63). Whereas, in this
project the reported NGF value represents the free NGF present in the extracellular fluid. The
Cmax in rats treated with chitosan and NGF was 1008.62 ± 130.02 pg/mL which was significantly
higher than that for rats given NGF only 97.38 ± 10.66 pg/mL (p = 0.014).
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The brain bioavailability of intranasally administered NGF was enhanced by ~14 fold as
calculated by ratio of area under the curve up to 6 h in chitosan vs non-chitosan groups (Figure
9). However, there was no significant difference in the elimination half life of NGF between
these two groups (Table 1).

Figure 9: Concentration-time profile of #GF in rat hippocampus following intranasal
administration. The data points represent baseline adjusted values and are averages of three
animals with SEM as error bars.
Parameters

I

GF group

I ( GF + 0.25% w/v
chitosan) group

p value

Cmax (pg/mL)

97.38 ± 10.66

1008.62 ± 130.02

0.014

AUC (pg h/mL)

209.79 ± 14.06

2692.46 ± 94.74

0.002

Elimination half life
(1/h)

0.45 ± 0.08

0.52 ± 0.05

0.06

Table 1: Pharmacokinetic parameters of intranasally (I#) administered #GF group and #GF +
0.25 % w/v chitosan group.
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CHAPTER-6
BRAI DERIVED EUROTROPHIC FACTOR

Brain-derived neurotrophic factor (BDNF) is one of the most important neurotrophic factors
which promote survival of all major neuronal types affected in neurodegenerative disorders and
also responsible for generation of cholinergic neurons in the basal forebrain and hippocampus
region (75-77). BDNF is capable of protecting neurons from amyloid peptides which are
neurotoxic in contrast to other members of neurotrophin family which are less effective in
rescuing neurons from these neurotoxins (78).
BDNF and its receptors are abundantly expressed in the central nervous system,
especially in the hippocampus and basal forebrain region (75, 77-81). This is the region of brain
in which most of the neurodegeneration is observed in case of Alzheimer’s, Parkinson’s,
Huntington’s disease, etc. Therefore, it is necessary to delivery BDNF to hippocampus and basal
forebrain region if one attempts to treat these disorders using BDNF.
In addition to its neuroprotective effect, BDNF plays a critical role in psychiatric
disorders like stress and depression (82). Decreased BDNF levels have been reported in various
animal models subjected to stress (83). In case of depression also, the expression of BDNF is
decreased. From the outcome of various studies, it has been hypothesized that presence of
normal level of BDNF in the brain is very important because of its ability to inhibit the cell death
cascades, modulate the plasticity and to increase the cell survival proteins (84-86).
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The regulation of BDNF expression by antidepressant drugs has been demonstrated. However,
the treatment of chronic depression condition using antidepressants is associated with a long
delayed onset of action and prolonged treatment duration (87, 88). In addition, the systemic side
effects associated with such prolonged antidepressant drug therapy is considerably high.
Shirayama et al., demonstrated the antidepressant effect of BDNF by infusing BDNF into
hippocampus of behavioral models of depression in (learned helplessness and forced swim test)
(89). There are various strategies employed for direct delivery of BDNF into the brain like direct
injection or by using minipumps or gene therapy (90, 91). Unfortunately, all these methods lack
practical clinical relevance and would result in significant systemic side effect (48). Bruke et al.,
observed that intracerebroventricular injection of BDNF resulted in relatively poor diffusion of
BDNF into the brain parenchyma. Moreover, BDNF when delivered systemically via parenteral
route is not bioavailable to the brain due to the metabolism of the peptide or due to the blood
brain barrier (BBB) and blood cerebrospinal fluid (BCSF) barrier (92). In addition, the
hydrophilic and macromolecular nature (~28kDa dimeric protein of non-covalently linked 14
kDa subunits) of the therapeutic agent limits its permeation across biological barriers (93).
Therefore, there is need for an alternative safe, non invasive route of delivery which bypasses the
BBB and delivers the drug to the affected regions of the brain over sustained time periods.

6.1. Materials and Methods
6.1.1. Chemicals
BDNF Emax ImmunoAssay system and rhBDNF were purchased from Promega Corporation,
Madison, WI. Freshly excised bovine olfactory mucosa was purchased from Pel-Freez
Biologicals (Rogers, AR).
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6.1.2. Preparation of chitosan and BD F solution
The chitosan solution was prepared by dissolving the required quantity of chitosan in a fraction
of 1% glacial acetic acid solution prepared in KRB buffer (pH 5.5). The second fraction of the
KRB buffer was used to dissolve the BDNF. The BDNF and chitosan solutions were mixed by
vortexing. The solutions prepared without incorporation of chitosan served as control.

6.1.3. In vitro permeation studies
In vitro experimental set up procedure is same as described in section 5.1.3. The donor
compartment was filled with 100 µL of BDNF solution (50 µg/mL prepared in KRB buffer) with
medium viscosity grade chitosan of different concentrations (0.1% or 0.25% or 0.5% w/v) and
the receiver compartment with 5 mL KRB buffer. Control set of experiments were run without
incorporation of chitosan in the donor solution. The amount of BDNF permeated across the
bovine olfactory mucosa was determined by assaying the samples collected from the receiver
compartment at the end of 2 h by ELISA using “BDNF Emax ImmunoAssay system” (see section
6.1.6).

6.1.4. Stability of BD F in the tissue homogenate
Freshly procured bovine olfactory mucosa of same weight was taken in a glass vial and
homogenized in KRB buffer. To this known concentration of BDNF was spiked and incubated at
370C for 12 h. Before the start of experiment, zero time point sample was taken to know the
initial activity of BDNF. Samples were withdrawn at regular intervals of time, diluted
accordingly and quantified by ELISA.

35

6.1.5. In vivo brain microdialysis
The in vitro calibration of microdialysis probes (CMA 12, CMA Microdialysis, Sweden) was
carried out by the method described by Vaka and Co-workers (94). Brain microdialysis was
carried out in male, Sprague dawley rats (250–300 g, Harlan Company, Indianapolis, IN, U.S.A)
under ketamine (80 mg/kg) and xylazine (10 mg/kg) anesthesia (i.p. injection). The experimental
procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at the
University of Mississippi (Protocol # 10–017). The rats were divided into 4 groups (n=3). The
first 3 groups of rats were laid on their back after anesthetizing and formulations were
administered intranasally using a microsyringe connected with a soft polymer capillary directly
into the posterior segment of the nose. Chitosan solution (0.25% w/v prepared in KRB buffer
was administered intranasally (vehicle control group) to group 1. BDNF solution prepared in
KRB (100 µL of 50 µg/mL) without incorporation of chitosan was administered intranasally to
group 2, whereas, BDNF solution (100 µL of 50 µg/mL) with 0.25% w/v chitosan prepared in
KRB was intranasally administered to group 3. To rats belonging to group 4, BDNF solution
(100 µL of 50 µg/mL) with 0.25% w/v chitosan prepared in KRB was administered via i.v route.
After administration of formulations to different groups the rats were secured on a
stereotaxic frame (Harvard Instruments, Holliston, MA) and brain microdialysis was carried out
by inserting the probe into the hippocampal region (anterior-posterior=5.6 mm, medio-lateral=5
mm, dorso-ventral=7 mm, from bregma) (94). The microdialysis probes (CMA 12) were
equilibrated by perfusing KRB at the rate of 2 µL/min using a microinjection pump for a period
of 1h. The rats were given maintenance doses of anesthesia [ketamine (40 mg/kg) and xylazine
(10 mg/kg)] after 3 h from the start of the study. The microdialysis samples were collected at
hourly intervals for 6 h and quantified by ELISA. The pharmacokinetic parameters were
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calculated using a noncompartmental pharmacokinetic model. The area under the curve was
calculated by trapezoidal rule.

6.1.6. Assay of BD F
The BDNF in the receiver compartments from in vitro experiments and the microdialysates from
in vivo studies were assayed by ELISA using “BDNF Emax ImmunoAssay system”
Elisa procedure:
Step 1) The required number of wells were coated with 100 µL of carbonate coating buffer
(0.025 M sodium bicarbonate and 0.025 M sodium carbonate, pH 9.7) containing anti-BDNF
mAb. The wells are covered and incubated overnight at 40C so that the antibody adheres to the
plastic through charge interactions.
Step 2) The wells were washed once with wash buffer (20mM Tris-HCl, 150mM sodium
chloride, 0.05% (v/v) tween 20) and 200 µL of Block & Sample buffer 1X was added and
incubated for 1h at room temperature so as to bind the non specific binding sites.
Step 3) The wells were washed once with wash buffer and BDNF standard (100 µL) were added
to each well of the first column by performing serial dilutions. Samples to be analyzed were
added to the wells starting from the second column. The wells were incubated with shaking for 2
h at room temperature.
Step 4) After 2 h the wells were washed 5 times using the wash buffer and 100 µL of Block &
Sample buffer 1X containing Anti-human BDNF pAb was added and incubated with shaking for
2 h at room temperature.
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Step 5) The wells were washed 5 times using the wash buffer and 100 µL of Block & Sample
buffer 1X containing Anti-IgY, horseradish peroxidase (HRP) conjugate was added and
incubated with shaking for 1 h at room temperature.
Step 6) The wells were washed 5 times using the wash buffer and 100 µL of TMB (3, 3’, 5,5”tetramethylbenzidine) solution was added to each well and incubated with shaking for 10
minutes at room temperature. The addition of TMB resulted in production of blue color due to
the reaction between TMB substrate and HRP conjugate.
Step 7) After 10 minutes the reaction was stopped by adding 100 µL of 1 N HCl and the samples
were analyzed using a plate reader at 450 nm.
The amount of NGF in the samples is proportional to the color generated in the oxidationreduction reaction. The sensitivity of the BDNF assay was about 7.8 pg/mL.

6.1.7. Pharmacodynamic studies
These studies were approved by the institutional animal ethical committee (Protocol #
VCP/IAEC/AB23-2010). The rats were divided into 5 groups (n=6). The first four groups of rats
were subjected to immobilization stress before carrying out the forced swim test by taping the
four limbs of rats to a wooden board with two metal loops around the neck for 2 h a day for
seven consecutive days. The formulations were administered 2 h prior to study on 8th day as
described in section 6.1.5 by anesthetizing the rats using isoflurane (5%). One more vehicle
control group of rats which were not subjected to immobilization stress (Group 5) was included
in these studies in order to determine the immobility time in the absence of stress. After the rats
were completely recovered from anesthesia they were placed individually in a glass container
with water at a depth of 30 cm (23–25°C) for 10 minutes. (89, 95). The immobility time of five
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groups of rats was recorded. Fresh water was used each time and the experiments were
performed during the same time of the day. The rats which were floating and making only the
necessary movements to keep its nostrils above the water surface were considered immobile.

6.2. Results and Discussion
6.2.1. Chitosan enhanced the in vitro permeation of BD F
Medium viscosity grade chitosan was found to enhance the BDNF permeation across the bovine
olfactory mucosa by ~7 fold, ~14 fold and ~5 fold at 0.1%, 0.25 % and 0.5% w/v concentration
respectively, over control (18.78 ± 16.69 ng/cm2) (Figure 10). The mechanism of permeation
enhancement could be due to a combination of several mechanisms. Vaka et al., reported earlier
that chitosan lead to a significant drop in the electrical resistivity of the mucosa indicating the
possible interaction of the polymer with the mucosal membrane (94).
The electrical resistivity was also found to recover with time suggesting that the
permeabilization of the membrane by the chitosan is reversible. It is likely that the drop in
electrical resistivity is due to opening of the tight junctions present in the membrane. However,
the role of ionic charge interaction between the polymer and BDNF, hydrokinetic transport and
other possible mechanisms cannot be overruled. Further, 0.25% w/v medium viscosity grade
chitosan was used to study its permeation enhancement efficiency in vivo.
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Figure 10: Effect of medium viscosity grade chitosan (MCH) at different concentrations on
in vitro permeation of BD#F across bovine olfactory mucosa. The data points provided are
an average of six trails with SEM as error bars.
6.2.2. Stability of BD F in the tissue homogenate
Olfactory mucosa has a milieu of enzymes in it (15). The enzymes serve a protective function to
prevent accidental entry of toxins via nose to brain pathway. BDNF being a peptide in nature is
very amenable to enzymatic degradation. It has been reported that there are several proteolytic
enzymes on the nasal mucosa surface, which could result in degradation of peptide and protein
drugs (36-38). Therefore, the stability of BDNF in the homogenate of the mucosal tissue was
investigated as it contains both inter and intracellular enzymes. The BDNF degradation followed
an apparent first order kinetics. The degradation rate constant calculated from the semi
logarithmic plot of percentage BDNF remaining as a function of time was found to be 0.39 ±
0.05 h-1. These studies indicate that the poor transport of BDNF across the olfactory mucosa is
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also likely due to significant degradation of BDNF in the membrane in addition to poor
membrane permeability.

6.2.3. In vivo brain microdialysis
In general, the total BDNF (bound and unbound) levels in the whole brain homogenates are
estimated (34, 87). However, the free or unbound levels of BDNF in the perineural fluid of rat
hippocampus are known to determine the drug activity and toxicity. Hence, microdialysis
technique was used in order to estimate the free BDNF levels. The recovery of microdialysis
probes was 2.98 ± 0.2 %. The BDNF levels in group one served as average baseline endogenous
levels (206.91 ± 56.94 ng/L). The time course of exogenous BDNF in the brain (the difference
between the total amount of BDNF and baseline endogenous level) was plotted and the
bioavailability parameters were calculated. The brain bioavailability of group 3 rats was
significantly enhanced by ~13 fold compared to group 2 (Figure 11). This increased
bioavailability could be attributed to chitosan which acts as a barrier modulating agent by
transient permeabilization of the olfactory mucosa.
In addition, some amount of BDNF may be transported by receptor mediated endocytosis
due to the presence of the physiologic receptor for BDNF (trkB) on mature olfactory neurons and
by intracellular transport (96). There was no significant enhancement of BDNF levels in case of
group 4 compared to group one (vehicle control). The Cmax achieved in group 3 rats at 2 h was
685.63 ± 94.37 ng/L which was significantly higher than the Cmax achieved (50.62 ± 35.85 ng/L)
in group 2 rats at 4 h.
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Figure 11: Concentration - time profile of BD#F in rat hippocampus following intranasal /i.v
administration of different formulations. The data points represent baseline adjusted values and
are averages of three animals with SEM as error bars.
However, the concentrations achieved in rat hippocampus upon intranasal administration at 60
min in our studies were less than that reported by Alcala-Barraza et al (1700 ± 600 ng/L) upon
intranasal administration of [125I]-BDNF (70 µg) (34). This difference in concentrations is due to
the fact that the authors have estimated the total amount of BDNF (bound and unbound) in tissue
homogenates. Kafitz et al., demonstrated that BDNF at a low nanomolar range excited neurons
in the hippocampus and cortex as rapidly (less than 10 ms) as the classic excitatory
neurotransmitter glutamate (97).
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6.2.4. Pharmacodynamic Studies
The forced swim test is one of the most commonly used paradigms to assess the effect of stress
on immobility time in rodent models (89, 98, 99). In this test the rats subjected to acute stress are
forced to swim in a restricted space from which they cannot escape. When rats are previously
subjected to stress leading to depression, the immobility time is increased (83, 89).
The immobility time of group 5 rats, which were not subjected to immobilization stress is ~
2 fold less than that of group 1 rats (Figure 12). Smith and coworkers have shown that repeated
immobilization of rats reduces BDNF levels in the rat brain, especially in the hippocampus (83).
Intranasal administration of formulation containing BDNF solution (100 µL of 50 µg/mL) with
0.25% w/v chitosan prepared in KRB to group 3 significantly decreased the immobility time
compared to that of group 1 (vehicle control group). These results clearly indicate the potential
of nose to brain delivery of BDNF formulations containing chitosan in replenishing the depleted
BDNF levels. Siuciak et al., and Shirayama et al., studied the effect of infusion of BDNF into the
rat brain on the immobility time and reported such similar observations (89, 100). The
antidepressant effect of BDNF is believed to be the result of interference of hippocampal
synaptic transmissions by BDNF with stress (89, 101-103) . In case of rats belonging to groups 2
and 4 the immobility time was not significant statistically (p > 0.05) compared to that of group 1
(vehicle control group). This is likely due to the poor brain bioavailability of BDNF as seen in
pharmacokinetics studies.
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Figure 12: The effect of BD#F on duration of immobility in the forced swim test upon
intranasal/i.v administration of formulations. The data points represent baseline adjusted
values and are averages of six animals with SEM as error bars (***p<0.001).
These studies showed that significant amounts of BDNF could be delivered to brain via nose to
brain pathway with the aid of barrier modulating agent like chitosan. Continuous stress in rats
leads to depression like condition, likely due to depletion of BDNF. Repletion of BDNF using
intranasal formulations can counteract the stress induced depression. Therefore, it appears that
intranasal delivery of BDNF with chitosan could potentially treat CNS disorders associated with
BDNF depletion.
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CHAPTER-7
CAR OSIC ACID

Carnosic acid (MW ~330 daltons), a phenolic diterpene isolated from rosemary (Rosmarinus
officinalis) leaves extract has been reported to promote the synthesis of NGF in the human
glioblastoma cells and enhance BDNF production in dopaminergic neuronal cell lines (104-106).
In addition, the carnosic acid is already known for its neuroprotective effect, antioxidant, antiinflammatory, antibacterial, anticancer and antiplatelet activity (106-111).

Figure 13: Structure of carnosic acid

7.1. Materials and Methods
7.1.1. Chemicals
Carnosic acid, Krebs ringer bicarbonate (KRB) buffer (premixed powder) and chitosan were
procured from Sigma chemicals (St. Louis, MO, USA). Acetonitrile and phosphoric acid were
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purchased from Fisher Scientific (Pittsburgh, PA, USA). Hydroxy propyl-beta-cyclodextrin (HPβ-CD) was procured from Roquette Pharma (Keokuk, IA, USA). All solutions were prepared in
deionized water. Brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF) Emax
ImmunoAssay systems were procured from Promega Corporation (Madison, WI). The bovine
olfactory mucosa was purchased from Pel-Freez Biologicals (Rogers, AR).

7.1.2. Analytical method
The amount of carnosic acid permeated across bovine olfactory mucosa (in vitro) was quantified
by measuring the samples collected from the receiver compartment using high performance
liquid chromatography (HPLC) system (Waters, 1525) with an autosampler (Waters, 717 plus)
consisting of a Phenomenex C18 (2) 100 R analytical column (4.6 mm X 150 mm, Luna, 5.0
mm) and a dual λ absorbance detector (Waters, 2487). Mobile phase consisted of acetonitrile and
0.1 % phosphoric acid solution (55:45, v/v) (111). Elution was performed isocratically at 250C at
a flow rate of 1.5 mL/min. Injection volume was 100 µL and the column effluent was monitored
at 210 nm. The range for the calibration curve was 50-1000 ng/mL (R2=0.99).

7.1.3. Phase solubility studies of carnosic acid
The phase solubility study was carried out to determine the stoichiometry according to the
method reported by Higuchi and Connors (112). An excess amount of carnosic acid was added to
solution of HP-β-CD prepared in KRB buffer at various concentrations (0.002—0.143 M). The
contents were stirred for 24 h at room temperature. After equilibrium the samples were filtered
and analyzed by HPLC.
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7.1.4. In vitro permeation studies
In vitro experimental set up procedure is same as described in section 5.1.3.
The donor and receiver compartments were filled with carnosic acid solution (500 µL of
1mg/mL) and 5 mL of KRB buffer + 20% HP-β-CD, respectively. The effect of different
concentrations of medium viscosity grade chitosan (0.1% or 0.25% or 0.5% w/v) on the
permeation of carnosic acid across bovine olfactory mucosa was studied. Control set of
experiments were run without incorporation of chitosan in the donor solution. Samples were
collected at 1 h intervals for 6 h and analyzed by HPLC.

7.1.5. In vivo brain microdialysis
In vitro calibration of microdialysis probes (CMA 12, CMA Microdialysis, Sweden) was carried
out according to the method reported by Vaka et al. (94). In vivo studies were carried out in
male, Sprague dawley rats (250-300 g, Harlan Company, Indianapolis, IN) under anesthesia
[ketamine (80 mg/kg) + xylazine (10 mg/kg); i.p injection]. The experimental procedures were
approved by the Institutional Animal Care and Use Committee (IACUC) at the University of
Mississippi (Protocol # 10-017). The rats were divided into 5 groups (n=3). To the first four
groups of rats, formulations were administered by intranasal (i.n) route whereas, to the fifth
group of rats formulation was administered by subcutaneous (s.c) route as stated below:
To group 1 rats, 0.25% w/v chitosan in HP-β-CD solution (vehicle control group) (i.n
route); group 2- carnosic acid (4 mg/kg) in HP-β-CD solution (i.n route); group 3-carnosic acid
(2 mg/kg): HP-β-CD solution with 0.25% w/v chitosan (i.n route); group 4-carnosic acid (4
mg/kg): HP-β-CD solution with 0.25% w/v chitosan (i.n route); group 5-carnosic acid: HP-β-CD
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solution with 0.25% w/v chitosan by s.c route (dose equivalent to that administered by i.n route
to group 4).
After four days of administration of different formulations to 5 groups of rats via
intranasal/s.c route, the brain microdialysis was carried out by securing the rats in the stereotaxic
frame (Harvard Instruments, Holliston, MA) and inserting the probe (CMA 12) into the
hippocampal region (anterior-posterior=5.6 mm, medio-lateral=5 mm, dorso-ventral=7 mm,
from bregma) (94). Intranasal formulations were administered to the rats by placing them on
their back after giving mild anesthesia and inserting a micro syringe connected with a soft
polymer capillary directly into posterior segment of the nose. The microdialysis probes were
equilibrated by perfusing KRB buffer at the rate of 2 µL/min using a microinjection pump for a
period of 1h. The microdialysis samples were collected after four days of administration
(intranasal/s.c route) of formulations and assayed for NGF (see section 5.1.8) and BDNF (see
section 6.1.6) by ELISA.

7.2.

Results and Discussion

7.2.1. Phase solubility studies of carnosic acid
The inherent aqueous solubility of carnosic acid was 25 ng/mL, whereas the solubility in case of
KRB buffer was 3 µg/mL. Phase solubility studies revealed that the carnosic acid solubility was
enhanced significantly with increase in concentration of HP-β-CD (Figure 14). The solubility of
carnosic acid was enhanced to 2.7 mg/mL at 20% HP-β-CD. However, the stoichiometry does
not appear to reflect a covalent or insertion complexation between HP-β-CD and carnosic acid.
Loftsson et al., demonstrated that the drug/cyclodextrin complexes can self associate to form
water soluble aggregates/microaggregates of several drug/cyclodextrin complex units which
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eventually solubilize water insoluble lipophilic drugs through non-inclusion complexation (113,
114).
Carnosic acid to

HP-~-CD

ratio was 1: 18 suggesting the formation of aggregates or a

micellar structures leading to enhanced solubility of camosic acid. Nevertheless, the solubility of
camosic acid was enhanced by

~900

fold at 20% cOl1centration of

HP-~-CD

over its inherent

solubility in KRB buffer. Hence, it was decided to use 1: 18 ratio of camosic acid:

HP-~-CD

in

further studies.
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Figure 14: Phase solubility diagram of carnosic acid at different concentrations of
hydroxypropyl fJ cyclodextrin (HP-fJ-CD). The data points provided are average offour trails
and error bars represent SEM

7.2.2. In vitro permeation studies of carnosic acid across bovine olfactory mucosa
Chitosan enhanced the permeation of camosic acid across the bovine olfactory mucosa by ~3 fold,
~8

fold and f"'W7 fold at 0.1 %, 0.25% and 0.5% w/v concentrations, respectively over control (17.20

± 6.67 J.lg/cm

2

)

(Figure 15). Recently, chitosan was reported to lead to a significant drop in the
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electrical resistivity of the mucosa indicating the interaction of the polymer with the mucosal
membrane.
Moreover, the electrical resistivity was also found to recover with time suggesting that
the permeabilization of the membrane by the chitosan is reversible. It is likely that the drop in
electrical resistivity is due to opening of the tight junctions present in the membrane (94). Such
similar observations were found using chitosan in other biological membranes (38, 67). As the
amount of carnosic acid permeated with the use of 0.25 % w/v chitosan was not significant
statistically (p > 0.05) compared to that of 0.5% w/v chitosan, 0.25% w/v chitosan was used to
develop intranasal formulation for in vivo studies.

Figure 15: Effect of different concentrations of chitosan (CH) on in vitro permeation of
carnosic acid across the bovine olfactory mucosa. The data points provided are average of four
trails and error bars represent SEM.
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7.2.3. Delivery of carnosic acid - In vivo
Carnosic acid was reported to promote the synthesis of NGF and BDNF in the human
glioblastoma and dopaminergic neuronal cell lines, respectively (104, 105). It has been reported
that the catechol portion of the carnosic acid play an important role in stimulating NGF synthesis
(104, 115). However, the exact mechanism of BDNF elevation by carnosic acid is still unclear.
In most of the neurodegenerative disorders, the degeneration is localized in the
hippocampus region of the brain. Therefore, it would be appropriate to monitor the levels of
neurotrophins in this region. Microdialysis is a minimally invasive technique of sampling
therapeutic agents from the tissue fluids. The method allows sampling of drug from specific
regions of the brain (68-72). Hence, microdialysis technique was employed in this study to
sample the free neurotrophin (NGF and BDNF) levels in the hippocampus region of rat brain.
The recovery of microdialysis probes in case of NGF studies was 4.2 ± 0.3%, whereas,
the recovery was found to be 2.98 ± 0.2% in studies involving BDNF. The endogenous NGF and
BDNF levels in the vehicle control group (group 1) were found to be 124.01 ± 28.06 ng/L and
206.91 ± 50.94 ng/L, respectively. The enhancement in the BDNF levels was about 50% in case
of group 2, which was significantly higher (p < 0.05) than the control group. On the other hand,
there was no significant enhancement in the NGF levels in group 2 over group 1. This suggests
that the threshold or effective concentration of carnosic acid to upregulate expression of
significantly high levels of NGF is relatively higher than that of BDNF, which was obviously not
attained with intranasal administration of only carnosic acid. In case of intranasal administration
of carnosic acid solution (2 mg/kg) with chitosan (group 3), the NGF and BDNF levels in the rat
hippocampus region were enhanced by ~3 and ~2 fold over group 1, respectively (Figures: 16 a

52

& b). It is most likely that the chitosan in the formulations enhanced the bioavailability of
carnosic acid, thus leading to a better biological response.
In order to study the effect of escalation of dose of carnosic acid on the upregulation of
BDNF and NGF, 4 mg/kg dose of carnosic acid solution with chitosan was administered via
intranasal route to group 4. Interestingly, there was no enhancement in the NGF levels but the
BDNF levels were enhanced by ~ 1.5 fold when compared to group 3 in which 2 mg/kg carnosic
acid solution with chitosan was administered via intranasal route (Figures: 16 a & b). These
findings were not in accordance with that reported by Kosaka and Yokoi, where they have
observed an increase in NGF synthesis (~25 fold) in the human gliobastoma cell lines by
carnosic acid in concentration dependent manner (5-100 µM) (104).
Additional mechanistic studies need to be carried out to explain the difference in dose
dependence response between in vitro and in vivo models. Till date there are no reports regarding
the mechanism of absorption of carnosic acid across mucosal membranes and the nature of dose
dependent pharmacokinetics of carnosic acid. Hence, further studies on these lines would explain
the differences observed between in vitro and in vivo results.
The systemic bioavailability of drugs is generally high following subcutaneous
administration as compared to non-parenteral routes. However, the bioavailability of drugs into
the brain may vary depending on physicochemical properties of drugs and the absorption
mechanism across the blood brain barrier. In this study, the levels of carnosic acid in the brain
could not be quantified. This was because the microdialysis recovery of carnosic acid was poor
due to high lipophilicity and poor water solubility. However, when carnosic acid solution (4
mg/kg) was administered via s.c route (group 5) there was again only a 50% increase in the
BDNF and NGF levels in the brain (Figures: 16 a & b). This suggests that the parenteral

53

administration would also deliver effective levels of carnosic acid into brain. However, frequent
administration and invasiveness limits the parenteral administration in patients.

Figure 16: Concentration of (a) nerve growth factor (#GF) and (b) brain derived neurotrophic
factor (BD#F) in rat hippocampus after four days of administration of carnosic acid
formulations by intranasal/s.c route. The data points represent average values of three animals
with SEM as error bars.
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CHAPTER-8
FORMULATIO OF CAR OSIC ACID A OPARTICLES

Nasal mucociliary clearance is one of the most important limitation for intranasal drug delivery
as it severely limits the residence time of drugs in the nasal cavity thereby effectively ruling out
the possibility of sustained nasal drug administration (116). Nanoparticulate drug delivery
systems have been reported to improve significantly the bioavailability of drugs upon intranasal
administration as compared to drug solutions (117-121). These formulations were shown to
increase the residence time in the nasal cavity and also protect the drugs from the enzymatic
degradation (121). Fernandez-Urrusuno et al., reported that upon intranasal administration of
chitosan nanoparticles loaded with insulin to rabbits, the plasma glucose levels was lowered to
60% of the original value. Whereas, the chitosan-insulin solution was found to lower the plasma
glucose levels to only 85% of the original value. The reason for this was stated to be due to the
intensified contact of the nanoparticles to the epithelium (118). In another study, it was reported
that cationic BiovectorTM nanoparticle system formulated using polysaccharides, dipalmitoyl
phosphatidyl choline and cholesterol had an extended mean residence half life of 2.3 h in the
human nasal cavity when compared to that of the residence half life (15-30 minutes) of solution
form (122, 123).
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On the basis of our previous study, our objective was to prepare carnosic acid nanoparticles
aiming to maintain prolonged therapeutic levels by increasing the residence time and thereby
reducing the frequency of administration.

8.1. Materials and Methods
8.1.1. Chemicals
Carnosic acid, chitosan, tripolyphosphate (TPP), glacial acetic acid were procured from Sigma
chemicals (St. Louis, MO, USA). Hydroxy propyl-beta-cyclodextrin (HP-β-CD) was procured
from Roquette Pharma (Keokuk, IA, USA). All other reagents and solvents used were of
analytical grade.

8.1.2. Formulation of nanoparticles
Experimental Design:
Central Composite Design (CCD) is a well suited response surface methodology (RSM)
employed for fitting a quadratic surface. This design is one of the commonly used RSM designs
employed for process optimization. CCD is used to establish the design space and optimize the
process parameters with lesser number of runs compared to other RSM designs. RSM
methodology is used in the present context to produce nanoparticles with optimum
physicochemical properties that are expected to produce the most desirable efficacy in vivo.
Face Centered Design (FCD) is a type of CCD which provides relatively high quality
predictions over the entire design space and do not require using points outside the original
factor range. Moreover, it has good design properties like little co-linearity, insensitive to outliers
and missing points. A 20-run, 33 Face centered design consisting of 3 factors at 3 levels was set

56

up using Design-Expert® 8.0.2 Demo version software to produce the carnosic acid loaded
nanoparticles. The effect of three critical factors namely chitosan concentration, TPP
concentration and sonication time on the responses like particle size, zeta potential, drug
encapsulation efficiency and drug release were systematically investigated. The factors and the
corresponding levels as per the design have been represented in Table 2.

Figure 17: Face Centered Design (FCD) depicting factorial () and axial points (O).
Carnosic acid loaded chitosan nanoparticles were prepared by ionic interaction. Different
concentrations of chitosan (4 mL of 0.1 or 0.55 or 1% w/v) were prepared to which carnosic acid
was added. Then, 1 mL of TPP solution (0.1 or 0.55 or 1 % w/v) was added. The solution was
ultrasonicated using a very high intensity microprobe with a diameter of 3.2 mm and a 100 W
high intensity processor (Microson XL-2000, VWR International, West Chester, PA, USA). The
probe was immersed into the solution and ultrasonication was carried out for 2 or 6 or 10
minutes and the nanoparticles were characterized immediately.
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8.1.3. Characterization of nanoparticles
The particle size and zeta potential of different batches of nanoparticles were determined by
Zetasizer Nano- ZS (Malvem Instruments Inc., Westborough, MA, USA). The particle size was
measured based on photon correlation spectroscopy (PCS or dynamic light scattering, DLS)
technique, which is a powerful tool for estimatil1g the particle size of fine particles ranging from
a few nanometers to micrometers (124). The zeta potential was determined based on
electrophoretic light scattering technique.

8.1.4. Determination of encapsulation efficiency
The encapsulation efficiency of different formulations was determined by separation of
nanoparticles from the aqueous suspension containing non-entrapped camosic acid by taking 200
f.lL of formulation in 0.5 mL centrifugal filter units and centrifuging at 5000 rpm for 7 minutes.
The solution collected in the tube after centrifugation was diluted accordingly and analyzed by
HPLC to determine the amount of free canlosic acid (see section 7.1.2). The encapsulation
efficiency (% EE) was calculated according to the equation below:
Total amount of camosic acid- Free amount of camosic acid
%EE

X 100
Total anlount of camosic acid

8.1.5. In vitro release study
Carnosic acid release from chitosan nanoparticles was determined by taking 1mL of the
formulation in a dialysis bag clamped at both ends. The dialysis bag was then placed in a beaker
containing 100 ml of 20% HP-~-CD solution with slow magnetic stirring at room temperature.
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Samples (10 mL) were withdrawn at regular intervals of time up to 12 h and replaced with same
volume to maintain sink conditions. The collected samples were diluted accordingly and
quantified by HPLC (see section 7.1.2).

8.1.6. In vitro mucoadhesion studies
These studies were carried out using bovine olfactory mucosa. A known amount of nanoparticles
(100 mg) was sprinkled on to the mucosa which was mounted on a glass slide. Then the glass
slide was placed in desiccator for about 15 minutes so as to allow the polymer to interact with the
membrane. After 15 minutes, the glass slide was taken out from the desiccator and was placed at
an angle of 450. The KRB buffer was circulated over the mucosa at the rate of 100 µL/min and
the washings were collected and freeze dried. The weight of the washed out nanoparticles was
determined and the percent mucoadhesion was calculated as follows (125).
% mucoadhesion = (Wi - Wf ) X 100/ Wi
Where, Wi is the weight of the nanoparticles applied to the mucosa and Wf represents the weight
of the nanoparticles washed out.

8.1.7. Atomic force microscopy (AFM) studies
The morphology and particle size measurements of the nanoparticles were performed by AFM
(PicoscanTM 2500, Molecular imaging corporation). The sample was prepared by depositing
nanoparticle solution on freshly cleaved mica surface and dried by nitrogen gas. Images were
acquired in non-contact mode using silicon nitrite cantilever with frequency of 150 KHz.
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8.1.8. In vivo studies
In vivo studies were carried out in male, Sprague dawley rats (250-300 g, Harlan Company,
Indianapolis, IN) under anesthesia [ketamine (80 mg/kg) + xylazine (10 mg/kg); i.p injection].
The experimental procedures were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Mississippi (Protocol # 10-017). The rats were divided
into 3 groups (n=3) each for (a) solution (administered only once), (b) solution (administered
daily once for four days) and (c) nanoparticulate formulation (administered only once).
To group 1 rats - 0.25% w/v chitosan (vehicle control group), to group 2 - carnosic acid
(4 mg/kg) with 0.25% w/v chitosan was administered by intranasal route and to group 3 carnosic acid with 0.25% w/v chitosan was administered by s.c route (dose equivalent to that
administered by intranasal route). After four days the rats were anesthetized and brain
microdialysis was carried out by securing them on the stereotaxic frame (Harvard Instruments,
Holliston, MA) and inserting the probe (CMA 12) into the hippocampal region. The
microdialysis samples were collected and assayed for NGF (see section 5.1.8) and BDNF (see
section 6.1.6) by ELISA.

8.1.9. Microscopic studies
In order to determine the toxicity of the formulations, rats treated with intranasal carnosic acid
formulations were euthanized and the olfactory tissue and brain were collected and fixed for 16 h
at 40C using freshly made, pre-chilled (40C) phosphate buffered saline (PBS)-4%
paraformaldehyde. The tissues were then washed in PBS for 20 minutes for 3 times at room
temperature, transferred into 65% ethanol (30 minutes), and finally transferred to 70% ethanol
for storage. Tissues were then trimmed and embedded in paraffin, sectioned and stained with
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hematoxylin and eosin for routine histological examination. Tissue sections were evaluated
histologically using an Olympus BX41 light microscope (Olympus America, Inc., Center Valley,
PA), and images were captured with an Olympus digital camera (model DP20) using appropriate
software supplied by the manufacturer.

8.1.10. Optimization
In order to test the potential of the carnosic acid nanoparticles, an attempt to optimize the
formulations was made by determining how various factors influence the physicochemical
properties of the nanoparticles. The effect of

three critical factors namely chitosan

concentration, TPP concentration and sonication time on the responses such as particle size, zeta
potential, drug encapsulation efficiency and drug release were systematically investigated (Table
2). The particle size is a key parameter that is assumed to dictate the in vivo absorption and drug
release kinetics whereas the zeta potential was known to determine the physical stability of the
formulation.

8.1.11. Regression analysis
The response parameters were statistically analyzed by applying one-way ANOVA at 0.05 level
using Design-Expert® 8.0.2 Demo version software. The individual parameters were evaluated
using the F test and Quadratic models as shown in equation were generated for each response
using multiple regression analysis (MLRA).
Y = β0 + β1 X1 + β2 X2 + β3 X3 + β11 X12 + β22 X22 + β33 X32 + β12 X1X2 + β23 X2X3 + β13 X1X3 +
+ β14 X1 X2X3
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Where Y is the level of the measured response, β0 is the intercept, β1 - β14 = regression
coefficients, X1 , X2 , X3 = Factors, X1 X2 , X2 X3 , X1 X3 represent the two-way Interaction terms
while X1X2X3 stands for three-way interaction.
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8.1. Results and Discussion
Formulation

0"\

w

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

TPP

Chitosan

(0A.)

(0h.)

0.55
1
1
0.55
0.1
0.1
0.1
0.55
1
1
0.55
0.1
0.55
0.1
1
0.55
0.55
0.55
0.55
0.55

0.55
1
0.1
0.55
1
0.1
0.1
0.55
1
0.1
0.55
1
0.1
0.55
0.55
0.55
1
0.55
0.55
0.55

Time
(minutes)
6
2
10
6
10
2
10
6
10
2
6
2
6
6
6
10
6
6
6
2

Particle size
(nm)
475.24 ± 12.15
374.67 ± 10.86
182.34 ± 15.40
410.45 ± 33.67
747.31 ± 59.82
310.12 ± 28.21
212.36 ± 21.02
495.21 ± 40.20
785.64 ± 68.31
250.27 ± 29.53
436.21 ± 36.77
831.25 ± 20.94
345.27 ± 37.30
625.72 ± 42.88
400.26 ± 39.14
354.12 ± 13.56
612.45 ± 60.28
471.69 ± 18.20
510.87 ± 31.13
568.64 ± 40.32

Zeta
potential (mV)
27.10 ± 3.21
18.20± 1.80
20.30 ± 2.03
28.50 ± 1.20
26.10 ± 1.16
34.30 ± 2.43
38.60 ± 2.8
25.90 ± 2.03
20.20 ± 1.65
23.60 ± 1.09
27.80± 1.55
24 ± 0.82
30.90 ± 2.61
34.10 ± 2.17
16.40 ± 2.30
34.60 ± 0.91
27.10 ± 2.63
30.60 ± 2.45
31.90 ± 2.82
26.70 ± 1.90

0A. EE

72.18 ± 3.26
40.98 ± 4.72
74.57 ± 2.48
75.36 ± 3.31
51.18 ± 6.20
74.93 ± 2.17
83.68 ± 2.08
68.22 ± 1.52
47.28 ± 1.97
64.57 ± 1.03
78.61 ± 2.95
57.32 ± 1.51
86.94 ± 2.03
76.57 ± 1.76
62.32 ± 1.33
80.19 ± 1.90
51.63 ± 2.83
77.06 ± 2.11
72.32 ± 1.48
68.32± 1.06

0/0 Release

(12 h)
29.44 ± 3.18
19.53 ± 1.07
32.76 ± 2.60
34.3 ± 2.81
23.58± 1.55
40.74 ± 1.76
52.52 ± 2.08
29.79 ± 2.61
18.66 ± 2.29
29.33 ± 1.57
37.42 ± 2.51
19.50± 1.68
50.46 ± 3.64
38.07 ± 3(;07
28.37 ± 2.33
34.89 ± 2.57
17.01 ± 2.96
48.32 ± 2.05
34.6 ± 1.68
28.94 ± 1.32

Table 2: The composition of20 formulations and the results obtainedfor particle size, zeta potential, % encapsulation efficiency and % release.

Summary of A OVA as per Design Expert version 8.0.2:
8.2.1. Particle size
Mathematical model is linear
TPP has a negative influence on the particle size while chitosan is found to have a positive
influence on the particle size as depicted by the mathematical model.
Source
Model
TPP
Chitosan
Lack of fit

d.f
2
1
1
12

Sum Square
474500
53814
420600
152800

Mean Square
237200
53814
420600
12735

F-value
25.24
5.73
44.76
9.15

Prob > F
< 0.0001
0.0285
< 0.0001
0.0119

Significance
Significant
Significant
Significant
Significant

Table 3: A#OVA for the particle size

‘Values of "Prob > F" less than 0.05 indicate model terms are significant, two factors were found
to be significant: TPP and chitosan concentration,
Extent of significance: Chitosan > TPP, (the F value suggest that chitosan has greater impact on
particle size than TPP)
Equation in terms of actual factors: Particle size = 308.99 – 163.02 X TPP + 455.77 X
chitosan
Contour plot: Portrayed a linear trend, the particle size was found to incease with decrease in
the TPP concentration while it was found to increase with increase in chitosan concentration.
The target particle size of 250 nm could be achieved using low concentration of chitosan (< 0.2%
w/v).
The plots are color coded, with blue representing the low values and red representing the high
values. The values increase as the color changes from blue to green to yellow to red.
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Particle size (nm)
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Figure 18: Contour plot showing the effect of chitosan and TPP conc on the particle size.
3-D plot: Particle size decreased linearly with decrease in the chitosan concentration while
fractionally declined with increase in TPP concentration.
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Figure 19: 3-D plot showing the effect ofTPP and chitosan concentration on the particle size.
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8.2.2. Zeta potential
Mathematical model is linear
TPP and chitosan have a negative influence on the zeta potential
Source

d.f

Model
TPP
Chitosan
Lack of fit*

2
1
1
12

Sum
Square
444.1
341.06
103.04
183.16

Mean Square

F-value

Prob > F

Significance

222.05
341.06
103.04
15.26

18.13
27.84
8.41
3.04

< 0.0001
< 0.0001
0.01
0.1138

Significant
Significant
Significant
Not Significant

Table 4: ANOVAfor the zeta potential
Values of "Prob > F" less than 0.05 indicate model terms are significant, two factors were found
to be significant: TPP and Chitosan concentration, Extent of significance: TPP > chitosan (The
F value indicates that TPP has greater impact on zeta potential compared to chitosan)
Equation in terms of actual factors: Zeta potential = 38.41 - 12.98 X TPP conc - 7.13 X
chitosan concentration.
Contour plot: Portrayed a linear trend, The zeta potential deceased with increase in the TPP and
chitosan concentrations.
Zeta Potential (mV)
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Figure 20: Contour plot showing the effect of chitosan and TPP cone on the zeta potential.
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The target zeta potential of 30 mV could be only achieved at TPP concentrations between 0.1 to
0.6% w/v and chitosan concentrations between 0.1-1 % w/v.
3-D plot: Shows a linear decrease in zeta potential with increase in the TPP concentration while
the change in zeta potential with increase in chitosan concentration was mot clearly distinct.
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Figure 21: 3-D plot showing the effect of chitosan and TPP cone on the zeta potential.

8.2.3. Encapsulation efficiency
Mathematical model is quadratic
Source

d.f

Model
TPP
Chitosan
Sonication
time
TPP 2
Chitosan 2

5
1
1

Sum
Square
2841.13
291.27
1857.96

1

Lack of fit*

Mean Square

F-value

Prob > F

Significance

568.23
291.27
1857.56

34.65
17.76
113.29

< 0.0001
0.0009
< 0.0001

Significant
Significant
Significant

94.68

94.68

5.77

0.0307

Significant

1
1

116.33
122.59

116.33
122.59

7.09
7.48

0.0185
0.0161

9

157.57

17.51

1.22

0.4366

Significant
Significant
Not
Significant

Table 5: ANOVAfor the encapsulation efficiency
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Values of "Prob > F" less than 0.05 indicate model terms are significant, two factors were found
to be significant, TPP and chitosan concentration.

Extent of significance: The F value indicates that, chitosan > TPP > Sonication time (chitosan
has the most pronounced influence on % EE compared to the other two factors)

Equation in terms of actual factors: Encapsulation efficiency = 74.7 + 20.75 X TPP conc +
3.33 X chitosan conc + 0.76 X sonication time - 29.77 X TPP conc z - 30.56 X chitosan conc z

Encapsulation efficiency (Chitosan vs TPP Cone)
Contour plot: Portrayed a curvilinear trend, the % EE deceased with increase in the chitosan
and TPP concentrations, the % EE can be maximized using low concentrations of chitosan (0.1 
0.2 % w/v) with TPP in the concentration range between 0.2 to 0.5% w/v.
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Figure 22: Contour plot showing the effect of chitosan and TPP concentration on encapsulation
efficiency.
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3-D plot: displays a curvilinear decline in % EE with increase in the chitosan concentration. But,
the influence of TPP on the % EE is not clearly demonstrated by the 3-D plots.
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Figure 23: 3-D plot showing the effect of chitosan and TPP concentration on encapsulation
efficiency.

Encapsulation efficiency (TPP conc vs Sonication time)
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Figure 24: Contour plot showing the effect of TPP concentration and sonication time on
encapsulation efficiency.
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Contour plot: Shows a curvilinear trend at low TPP concentration and later tends to become
linear at high TPP concentration. The % EE can be maximized at high sonication time with TPP
in the concentration range between 0.25 to 0.45%.

3-D plot: displays a curvilinear decline in % EE with increase in the TPP concentration.
However, the positive influence of TPP concentation on % EE seem to be less evident.
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Figure 25: 3-D plot showing the effect of TPP concentration and sonication time on

encapsulation efficiency.

Encapsulation efficiency (Chitosan conc vs Sonication time)
Contour plot: Show a curvilinear trend at low chitosan concentration and linear trend at high
chitosan concentration. The % EE can be maximized using low concentration of chitisan (0.1 
0.2% w/v).
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Figure 26: Contour plot showing the effect of chitosan concentration and sonication time on
encapsulation efficiency.

3-D plot: displays a curvilinear decrease in % EE with increase in chitosan concentration. The
influence of sonication time on the % EE is not clearly obvious in the plots below
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Figure 27: 3-D plot showing the effect of chitosan concentration and sonication time on
encapsulation efficiency.
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8.2.4. % Release

@

12h

Mathematical model generated was found to be linear
Source

d.f

Model
TPP
Chitosan
Lack of fit*

2
1
1
12

Sum
Square
1356.97
200.7
1156.27
411.45

Mean Square

F-value

Prob > F

Significance

678.49
200.7
1156.27
34.29

17.72
5.24
30.20
0.72

< 0.0001
0.0351
< 0.0001
0.7069

Significant
Significant
Significant
Not Significant

Table 6: ANOVAfor the % release

@

12 h

Values of "Prob > F" less than 0.05 indicate model terms are significant, two factors were found
to be significant: TPP and chitosan concentration.
Extent of significance: The F value signifies that chitosan > TPP (chitosan concentration was found
to have a greater influence on the release

@

12 h compared to TPP concentration)

Equation in terms of actual factors: % Drug release

@

12 h = 51.07 - 9.95 X TPP concentration

(%) - 23.89 X chitosan concentration (%)
% Release @ 12h (Chitosan vs TPP cone): Contour plot is found to be linear.
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Figure 28: Contour plot showing the effect of chitosan and TPP conc on % release
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@

12 h

Chitosan and TPP concentrations were found to exert a negative influence on the release

@

12 h.

The target release (50% @ 12 h) would be plausible at low concentrations of chitosan and TPP
(0.1-0.2% w/v)

3-D plot: The drug release is shown to decrease linearly with increase in the concentration of
chitosan. The influence of TPP on the drug release seems to be less evident in the plots.
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Figure 29: 3-D plot showing the effect of chitosan and TPP cone on % release @12 h

Chitosan nanoparticles are generally formulated by chemical cross-linking with different kinds
of polyanions (glycyrrhetic acid, polyaspartic acid, etc.) and other oppositely charged molecules
yielding controlled drug release formulations with less toxicity (126, 127). However, the most
extensively used polyanion is tripolyphosphate. Chitosan - TPP nanoparticles were formed by
means of electrostatic interaction between the positively charged amino groups of chitosan and
negatively charged phosphate and hydroxide groups of TPP aqueous solution, which compete
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type of interaction were reported to have strong adhesion and immediate immobilisation on to
negatively charged mucosal surfaces (129).
The particle size was found to increase with increase in chitosan concentration while it
was found to increase with decrease in the TPP concentrations. The geater influence of the
chitosan on the particle size compared to the TPP concentration is clearly obvious from the 3-D
plot (Figure 19). The increase in particle size could be attributed to the increase in viscosity of
the polymer solution due to increase in polymer concentration. The target particle size of 250 nm
could be achieved using low concentrations of chitosan (< 0.2% w/v). The zeta potential plays an
important role in the interactions with mucin glycoproteins, (that is the olfactory mucosa) as well
as it influences physical stability. The zeta potential was found to decrease with increase in the
TPP concentration while it was marginally decreased with increase in chitosan concentrations.
The target zeta potential of 30 mV could be only achieved at TPP concentrations between 0.1 to
0.6% w/v. The plots indicate that % EE decreased with increase in the chitosan and TPP
concentrations, therefore, the % EE can be maximized using low concentrations of chitosan with
TPP in the concentration range between 0.2 to 0.5% w/v. In addition, the % EE can be
maximized at high sonication time. Chitosan and TPP were found to exert a negative influence
on the release @ 12 h. The plots portray that the target release (50% @ 12 h) would be plausible
at low concentrations of chitosan and TPP (0.1-0.2% w/v). The drug release was shown to
decrease linearly with increase in the concentration of chitosan. However, the influence of TPP
on the drug release was seen to be less evident from the plots.
The mathematical models generated were validated by preparing further three new
formulations which differed totally in composition and processing time from the model
formulations employing desirability approach. Constraints were set on each of the responses
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(particle size ~250 nm, zeta potential ~30 mV, maximum encapsulation efficiency and ~50%
release in 12 h) to establish the composition of the new formulations (Table 7). The new
formulations developed were evaluated and the experimental values of the responses were
compared with those predicted by the mathematical models. The comparison of the two sets of
values

along

with

the

prediction

error
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involved

is

shown

in

Table

8.

Formulation
No

TPP
cone (%)

Chitosan
cone (%)

Sonication
time (Min)

Particle
size (nm)

Zeta
Potential
(mV)

effeciency

% Drug
Release @
12 h

21
22
23

0.80
0.55
0.65

0.10
0.10
0.10

7.25
10.00
5.65

224.20
264.65
248.73

27.31
30.53
29.26

77.87
84.82
80.01

40.72
43.19
42.22

% Encap

Desirability

0.823
0.818
0.812

Table 7: The results ofthe optimizedformulations obtainedfor particle size, zeta potential, % encapsulation
efficiency and % release.

~

Table 8: Comparison ofexperimentally observed responses ofthe optimizedformulations with that ofthe
predicted responses.
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Figure 30: Contour plot offormulation 23, showing the value of desirability at
different concentrations of chitosan and TPP.
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Figure 31: 3-D plot offormulation 23, showing the value of desirability at
different concentrations of chitosan and TPP.
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The prediction error for the response parameters of formulation 23 was found to be range from
-4.19 to 14.48 that was much lesser when compared to that of formulations 21 & 22. The low
values of the prediction error proved the validity of the mathematical models generated by
ANOVA and multi linear regression analysis (MLRA). Considering the low prediction error, the
formulation 23 was used to carry out in vitro mucoadhesion, AFM, in vivo and microscopic
studies.
The in vitro mucoadhesion studies carried out across bovine olfactory mucosa indicated
that the percent mucoadhesion of the nanoparticles decreased from 86% to 73% over a period of
6 h. AFM studies revealed the size of the nanoparticles to be ~250 nm.
Upon intranasal administration of 0.25% w/v chitosan solution (vehicle control group) to
group 1 rats the endogenous NGF and BDNF levels were found to be 124.01 ± 28.06 ng/L and
206.91 ± 50.94 ng/L, respectively. Whereas, upon intranasal administration of 4 mg/kg carnosic
acid solution with chitosan (0.25% w/v) to group 2 rats the NGF levels were enhanced by ~3.2
fold and the BDNF levels by ~2.7 fold as compared to control group. However, when carnosic
acid solution (4 mg/kg) was administered via subcutaneous route (group 3) there was ~50%
increase in the BDNF and NGF levels in the brain compared to control group. Interestingly,
when these formulations were administered in the form of nanoparticles only once in contrary to
that of solution which was administered daily once for a period of 4 days there was no
statistically significant difference in the NGF and BDNF levels between the 3 groups of rats
(Figure 32). However, when the formulations were administered in the form of solution only
once, the NGF and BDNF levels even after 4 days were not statistically significant from the
vehicle control group. These results clearly indicate that carnosic acid nanoparticles could reduce
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the frequency of administration and also could maintain prolonged therapeutic levels due to
higher retention time at the site of delivery.

Figure 32: Concentration of #GF and BD#F in the rat hippocampus after administration of
carnosic acid formulations [solution administered daily once for 4 days and nanoparticles (#Ps)
administered only once].
Microscopic studies of hematoxylin and eosin stained olfactory and brain sections from treated
and control animals was performed.

Figure 33: Representative pictures of rat olfactory tissue belonging to (a) untreated group
(b) treated with intranasal formulation of carnosic acid and chitosan.
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In all animals the brain was architecturally normal. Additionally, no cytopathologic
abnormalities i.e., apoptosis/necrosis of neurons or glial cells, inflammatory infiltrates, or glial
scars were found. The tissues are architecturally and histologically normal. These studies
demonstrate that the intranasal administration of formulations containing carnosic acid and/or
chitosan has no adverse affects even upon frequent administration.

Figure 34: Histology of the dentate gyrus of the hippocampus (20 X magnifications,
bar=500µm) A. Untreated (control) B. Carnosic acid (4mg/kg) treated C. Carnosic acid
(4mg/kg) and chitosan (0.25% w/v) treated. Histologically normal neurons and glial cells of the
dentate gyrus of the hippocampus (400X magnification, bar=20µm) D. Untreated (control). E.
Carnosic acid (4mg/kg) treated F. Carnosic acid (4mg/kg) and chitosan (0.25% w/v) treated.
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The novel findings of this study indicates that the nose-brain delivery of small molecular size
therapeutic agents like carnosic acid along with chitosan as barrier modulating agent in the form
of nanoparticles will have a significant positive impact on the treatment of broad-spectrum
neurodegenerative and CNS disorders. The brain bioavailability following parenteral
administration appears to be poor. Therefore, the intranasal delivery strategy would circumvent
the limitations associated with parenteral delivery.
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CHAPTER-9
DELIVERY OF A TIBIOTICS

Meningitis is an infection of the cerebrospinal fluid and meninges that surround the brain and
spinal cord. Bacterial meningitis is primarily caused by three main bacterial species (Neisseria
meningitidis, Streptococus pneumonia, Haemophilus influenza type B) and it accounts to three
fourth of the meningitis infected world population. Bacterial meningitis is more common in
African, American and Asian countries. Generally, it is treated using large doses of antibiotics
such as chloramphenicol and cephalosporins (72, 130, 131). Effective levels of antibiotics should
be maintained in the brain all through the treatment period for successful treatment of meningitis.
In most of the developing countries, despite their greater potency, the use of cephalosporins is
limited due to their high cost.
Cefotaxime is one of the cephalosporins recommended for the treatment of bacterial
meningitis and is generally administered via parenteral or oral route (132-134). The systemic
delivery of cephalosporins including cefotaxime is associated with the potential risk of causing
severe systemic side effects (135-137). Moreover, the drug has short elimination half-life in the
brain, hence frequent administration is inevitable during the treatment. Therefore, there is need
for a patient compliant method to deliver cefotaxime to the brain.
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9.1. Materials and Methods
9.1.1. Chemicals
Cefotaxime sodium salt, chitosan (MW ~250 kDa, 75-80% deacetylation), Krebs-ringer
bicarbonate (KRB) buffer (premixed powder), 1-butanol, potassium phosphate (monobasic) were
procured from Sigma chemicals (St.Louis, MO, USA).Chloroform, phosphoric acid and
acetonitrile were obtained from Fischer Scientific (Atlanta, GA,USA).

9.1.2. In vitro permeation studies
In vitro experimental set up procedure is same as described in section 5.1.3.
The effect of different concentrations of chitosan (0.1% w/v and 0.25% w/v) on the
permeation of cefotaxime was investigated by taking 500 µL of drug solution with chitosan in
the donor compartment. The receiver compartment was filled with KRB buffer (5 mL). Drugchitosan solution was prepared by dissolving the required quantity of chitosan in 1% glacial
acetic acid solution in KRB buffer followed by addition of cefotaxime (1 mg/mL). Control set of
experiments were run without incorporation of chitosan in donor solution. The amount of
cefotaxime permeated across the olfactory mucosa was determined by analyzing the samples
collected from the receiver compartment by HPLC.

9.1.3. Analytical method
The HPLC system (Waters, 1525) consisting of a Phenomenex C-18 analytical column (4.6 mm
X 150mm, Luna 5.0µ) and a variable wavelength detector (Waters, 2487) was used. The mobile
phase was made up of 0.007M phosphoric acid in water-acetonitrile (85:15 v/v). The flow rate
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was 1.3 mL/min and the column effluent was monitored at 254 nm. The range of calibration
curve was 0.025 µg/mL to 1 µg/mL (R2 = 0.99) (138).

9.1.4. Extraction of cefotaxime
The plasma obtained from untreated rats was spiked with known concentrations of cefotaxime
and calibration curve was plotted using the analytical method.
The rat plasma samples containing cefotaxime were extracted initially by vortexing 1mL
of plasma with 0.4 M HCl. Then 7 mL of chloroform-1-pentanol (3:1) was added to the mixture
and vortexed for 30 minutes followed by centrifugation for a period of 10 minutes at 1000 g.
From this organic phase (5 mL) was collected and 350 µL of phosphate buffer (pH 7) was added
to it so as to back extract (30 minutes) the cefotaxime which was then centrifuged for a period of
10 min. The upper aqueous phase was quantified by HPLC (139).

9.1.5. In vivo brain microdialysis
Pharmacokinetic studies were carried out in Sprague Dawley rats (male, 250-300 g; Harlan
Company, Indianapolis, IN, USA). The experimental procedures were approved by the
Institutional animal care and use committee (IACUC) at the University of Mississippi (Protocol
# 10-017). The rats were categorized into four groups (n=3 for groups 1 & 2 and n=6 for groups
3 & 4). The rats were anesthetized using ketamine (80 mg/kg) and xylazine (10 mg/kg) (i.p
injection).
Cefotaxime solution with 0.25% w/v chitosan (40 mg/kg) was administered by i.v route
to rats in groups 1 & 3 and intranasally (i.e. administration of drug directly into the posterior
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segment of the nose using a microsyringe connected with a soft polymer capillary) to groups 2 &
4.
In case of rats belonging to groups (1 & 2), the time course of drug in the brain was
investigated by performing microdialysis. The microdialysis probe (CMA 12) was inserted into
brain (anterior-posterior=5.6 mm, medio-lateral=5 mm, dorso-ventral=7 mm, from bregma) after
securing the rat on a stereotaxic frame (Harvard Instruments, Holliston, MA, USA). The
microdialysis probes were equilibrated by perfusing KRB buffer at 2 µL/min for a period of 30
minutes with the aid of a microinjection pump. Following i.v or intranasal administration of
cefotaxime solution (10 mg in 100 µL) the microdialysis fractions were collected at 15, 30, 60,
90, 120, 180, 240, 300 and 360 minutes and quantified using HPLC.
In case of groups 3 and 4 blood samples were collected at 15, 30, 60, 90, 120, 180, 240,
300 and 360 minutes from retro-orbital plexus using heparinized capillary tubes. Plasma was
collected from blood samples by centrifuging at 1500 rpm for 15 minutes and cefotaxime was
analyzed using HPLC after extraction with a hydrochloric acid, chloroform-1-pentanol (3:1) and
phosphate buffer solvent system.

9.1.6. Pharmacokinetic data analysis
The area under curve (AUC) was calculated using trapezoidal rule, Cmax and tmax were directly
obtained from the concentration-time graphs.
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9.2. Results and Discussion
9.2.1. In vitro permeation studies
Chitosan (0.25% w/v) enhanced the permeation of cefotaxime across bovine olfactory mucosa
by ~1.5 fold and ~2 fold at the end of 1st h and 2nd h respectively, over control (29.56 ± 6.18
µg/cm2). Whereas, there was no significant enhancement in permeation of cefotaxime at 0.1%
w/v concentration of chitosan (Figure 35). Overall, the enhancement in the permeability of drug
by chitosan was not as dramatic as that observed in case of NGF (94).

Figure 35: Effect of chitosan (0.1 % or 0.25% w/v) on in vitro permeation of cefotaxime across
the bovine olfactory mucosa. The data points provided are average of four trails and error bars
represent SEM.

Therefore, a solution of drug in 0.25% w/v chitosan was used for intranasal and intravenous
administration in further studies. Further, higher concentrations were not considered due to

86

increased viscosity of the formulation, which might cause discomfort upon intranasal
administration in rats.

9.2.2. Pharmacokinetics of cefotaxime in the brain
The in vitro recovery of microdialysis probes was found to be 12.84 ± 1.42%. The recovery of
cefotaxime from plasma was 39.60 ± 3.25%.
The Cmax of cefotaxime in the brain following intranasal administration (1.477 ± 0.19
µg/mL) was found to be less than that observed upon i.v administration (3.286 ± 1.17 µg/mL).
This difference in Cmax is likely because of drug loss due to absorption of a greater fraction of
drug from nasal mucosa into the systemic circulation followed by elimination via normal
clearance. Such similar kind of observations using tetramethylpyrazine was reported earlier by
Hussian and co-workers as well as Illum (3, 140). Moreover, the bioavailability (AUC0-∞) of
cefotaxime in the brain following intranasal administration (0.38 ± 0.06 X 103 min.µg/mL) was
not significantly different from the bioavailability (AUC0-∞) following i.v administration (0.45 ±
0.06 X 103 min.µg/mL) (Figure 36).
However, the time required to achieve maximum concentration (tmax) was less upon
intranasal administration (30 minutes) compared to i.v administration (180 minutes). Similar
observations have been reported in case of tetramethylpyrazine. Feng et al, suggest that rapid
absorption of drug via olfactory region could be due to convective transport of drugs. This
ability of drugs to pass through multiple pathways from nose to brain when administered
intranasally was previously reported (3).
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The minimum concentration at which the drug has the ability to inhibit the bacterial growth is
defined as Minimum Inhibitory Concentration (MIC). The MIC levels of cefotaxime against
most bacteria causing meningitis range from 0.01 µg/mL to 0.6 µg/mL (135). From figure 36 it
is evident that the drug delivered intranasally attained MIC levels rapidly and remained high over
the MIC through 6 h which is comparable to i.v administration.

Figure 36: Concentration- time profile of cefotaxime in rat hippocampus following intranasal
/i.v administration. The data points represent baseline adjusted values and are averages of three
animals with SEM as error bars.
Provided this data is translatable to humans, it appears that effective levels of drug could be
achieved in the brain quite rapidly via intranasal administration of drug and frequent
administration would keep the drug levels fairly consistent through the treatment duration.
Although the brain levels of cefotaxime are higher following i.v administration (Figure 36),
intranasal route may be preferred over i.v route because of noninvasiveness and potentially
minimal side effects. Moreover, overshooting the MIC levels in the brain, as seen in case of i.v
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route is not likely to improve the treatment but rather could cause toxicity in case of certain
drugs with small therapeutic window.
The bioavailability of drug in the brain following i.v administration was expected to be
higher than intranasal administration. However, the overall brain uptake following i.v
administration was found to be comparable to that of intranasal. This could be attributed to the
rapid hepatic metabolism of drug in the systemic circulation. The major metabolic organ for
cefotaxime was found to be liver (141, 142). Earlier Tsai et al., reported a Cmax of ~1.9 µg/mL in
the brain following intravenous administration which is ~2 fold less compared to the present
case. However, the bioavailability (AUC0-t) did not differ significantly between these two
studies.

9.2.3. Pharmacokinetics of cefotaxime in plasma
The drug levels in plasma following intranasal administration were almost an order of magnitude
less when compared to that of i.v administration (Figure 37). The AUC0-∞ levels following
intranasal administration and i.v administration were 15.32 ± 3.42 X 103 min.µg/mL and 371.30
± 191.02 X 103 min.µg/mL, respectively. This data suggests that the drug is likely to undergo
metabolism in the mucosal membrane. However, low systemic bioavailability following
intranasal administration is likely to result in less systemic side effects compared to parenteral
administration.
The absolute bioavailability of cefotaxime following intranasal administration was 0.041
± 0.009. This data suggests that the systemic side effects are likely to be less when cefotaxime is
administered by intranasal route as compared to intravenous administration.
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Figure 37: Concentration-time profile of cefotaxime in rat plasma following intranasal /i.v
administration. The data points represent baseline adjusted values and are averages of three
animals with SEM as error bars.

Cefotaxime was found to undergo enzymatic metabolism in the liver to

desacetylcefotaxime

(141, 142). It was also reported that desacetylcefotaxime has only 12% antibacterial activity
compared to cefotaxime (143). From figure 37 it is evident that the amount of drug that enters
into the plasma when administered intranasally is less compared to i.v and hence, will metabolize
to a less extent than administered and retains its antibacterial activity. Apart from retaining its
activity the unwanted systemic side effects may be minimized.
It was reported that distribution of cefotaxime following i.v administration was
instantaneous and extensive in body resulting in rapid equilibration between most body fluids
and tissues (142, 144). As the amount of drug in plasma when administered intranasally is less
than i.v (Figure 37), distribution of drug to body fluids and tissues may be comparatively less
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which may be an additional factor to minimize the unwanted effects of drug in body fluids and
tissues following intranasal administration.
These results indicate that intranasal delivery of antibiotics such as cefotaxime would be
a potential treatment approach for bacterial meningitis. In addition, Nose to brain delivery of
cefotaxime is non-invasive, allows frequent administration and would minimize the side effects
associated with systemic delivery.
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Conclusions
Considerable anatomical differences between human and rats with respect to olfactory mucosa
and the brain may influence how the current results translate into human applications. In rats, the
nasal olfactory mucus covers approximately 50 % of the total nasal epithelium as opposed to 5%
in humans. The cerebrospinal fluid volume (~160 mL in humans vs 0.25 mL in rats) is replaced
every 1.5 h in rats compared to every 5 h in humans. The brain interstitial fluid volume is ~260
mL in humans versus 0.3 mL in rats. Therefore, the drug levels achieved in rats by intranasal
administration may be an overestimation of what could actually be achieved in humans.
However, these facts reinforce the necessity of drug bioavailability enhancers like chitosan for
achieving clinically efficacious levels of drug in the human brain via the nasal pathway given the
small mucosal area.
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